Jpeh的个人主页 - 老虎社区

Jpeh

Jpeh

暂无个人介绍

IP属地：未知

258关注

0粉丝

1主题

0勋章

2021-06-04

Good read!

Where Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote>

2021-06-28

Good read!

抱歉，原内容已删除

2021-06-03

Incredible

抱歉，原内容已删除

2021-02-01

Nice

抱歉，原内容已删除

2021-06-11

Agree!

抱歉，原内容已删除

2021-02-14

Great to know

抱歉，原内容已删除

2021-02-02

Nice

抱歉，原内容已删除

2021-06-15

Good to know

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>

2021-06-15

Good to know

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>

2021-06-14

Good read

Chip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3550499772816891","uuid":"3550499772816891","gmtCreate":1587405908956,"gmtModify":1612149108522,"name":"Jpeh","pinyin":"jpeh","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":258,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.22","exceedPercentage":"80.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.13","exceedPercentage":"80.62%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":150149054,"gmtCreate":1624890796078,"gmtModify":1633947401345,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150149054","repostId":"1103992527","repostType":4,"isVote":1,"tweetType":1,"viewCount":1645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160075690,"gmtCreate":1623767905210,"gmtModify":1634028595287,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good to know","listText":"Good to know","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160075690","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=zh_CN&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-15 17:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160072591,"gmtCreate":1623767892913,"gmtModify":1634028595988,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good to know","listText":"Good to know","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160072591","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=zh_CN&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-15 17:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185776661,"gmtCreate":1623676310853,"gmtModify":1634030252598,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185776661","repostId":"1182855398","repostType":4,"repost":{"id":"1182855398","kind":"news","pubTimestamp":1623663435,"share":"https://www.laohu8.com/m/news/1182855398?lang=zh_CN&edition=full","pubTime":"2021-06-14 17:37","market":"us","language":"en","title":"Chip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182855398","media":"benzinga","summary":"The ongoing global semiconductor shortage is boosting business opportunities for semiconductor indus","content":"<p><div> The ongoing global semiconductor shortage is boosting business opportunities for semiconductor industry intermediaries, or authorized distributors, as they are able to source parts faster, according ...</p><p><blockquote><div>持续的全球半导体短缺正在增加半导体行业中介或授权分销商的商机，因为他们能够更快地采购零件...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">benzinga</strong><span class=\"h-time small\">2021-06-14 17:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The ongoing global semiconductor shortage is boosting business opportunities for semiconductor industry intermediaries, or authorized distributors, as they are able to source parts faster, according ...</p><p><blockquote><div>持续的全球半导体短缺正在增加半导体行业中介或授权分销商的商机，因为他们能够更快地采购零件...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AVGO":"博通","ARW":"艾睿","INTC":"英特尔","AVT":"安富利电子"},"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182855398","content_text":"The ongoing global semiconductor shortage is boosting business opportunities for semiconductor industry intermediaries, or authorized distributors, as they are able to source parts faster, according to the WSJreport.\nWhat Happened:Services of electronic component distributors such as Avnet Inc(NASDAQ:AVT) andArrow Electronics Inc(NYSE:ARW) are increasingly sought after from bigger companies such as Intel Corp(NASDAQ:INTC), Samsung Electronics and others, who generally rely on direct purchases and are able to secure supplies on their own, WSJ reported Sunday.\nAs per Peggy Carrieres, Avnet’s vice president for global sales, large buyers are treading on uncharted territory as they engage directly with distributors to hedge against supply chain disruptions or keep tabs on a host of different materials.\nAvnet is an authorized distributor for Intel andBroadcom Inc(NASDAQ:AVGO).\nAs a result, distributors are able to charge more than the usual 10% commission. In addition, higher prices and shipping volumes amid the pandemic have boosted bottom lines for distributors despite an ongoing shortage.\nArrow Electronics, one of the industry’s biggest distributors, saw its operating income from the global components business rise more than 70% in the first three months of the year. Avnet sales rose 14% from a year earlier to $4.9 billion for the quarter ended March 31.\nWhy It Matters:The global chip shortage has forced automakers across the world to halt production lines and the shortage is now impacting consumer electronics as well, includingApple Inc(NASDAQ:AAPL).\nSemiconductor prices have shot up amid the crisis and brokers are quoting five times higher prices than before the pandemic for auto chips, as per WSJ; in some extreme cases, it's reportedly 20 times more.\nPrice Action:Shares of Avnet, which have risen 25% so far this year, closed 1% higher at $43.9 on Friday. Arrow Electronics shares, which have risen 24% year-to-date, closed 0.25% lower at $120.9 on Friday.","news_type":1,"symbols_score_info":{"ARW":0.9,"INTC":0.9,"AVT":0.9,"AVGO":0.9}},"isVote":1,"tweetType":1,"viewCount":2456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188169824,"gmtCreate":1623424494068,"gmtModify":1634033330380,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Agree!","listText":"Agree!","text":"Agree!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188169824","repostId":"1146386859","repostType":4,"isVote":1,"tweetType":1,"viewCount":1837,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183944232,"gmtCreate":1623303731526,"gmtModify":1634034763662,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/183944232","repostId":"2142249026","repostType":4,"isVote":1,"tweetType":1,"viewCount":1492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114502700,"gmtCreate":1623078133800,"gmtModify":1634037180944,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114502700","repostId":"1165309768","repostType":4,"isVote":1,"tweetType":1,"viewCount":1736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":116568006,"gmtCreate":1622812572205,"gmtModify":1634097783234,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/116568006","repostId":"1122373606","repostType":4,"repost":{"id":"1122373606","kind":"news","pubTimestamp":1622793373,"share":"https://www.laohu8.com/m/news/1122373606?lang=zh_CN&edition=full","pubTime":"2021-06-04 15:56","market":"us","language":"en","title":"Where Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122373606","media":"seekingalpha","summary":"Summary\n\nApple has been a great investment over the last decade, but the next decade may look quite ","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has been a great investment over the last decade, but the next decade may look quite different.</li>  <li>Apple has seen its growth slow down over the last decade, and it will likely not be a growth monster in the coming years, either.</li>  <li>Shares have ample long-term upside, but investors should consider the current valuation before jumping to decisions.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f2ea192ed76d9772c2c6a820098faf5\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>Photo by Paopano/iStock Editorial via Getty Images</span></p><p><blockquote><ul><li>苹果在过去十年中是一项伟大的投资，但下一个十年可能会大不相同。</li><li>苹果的增长在过去十年中有所放缓，未来几年也可能不会成为增长怪物。</li><li>股价具有充足的长期上涨空间，但投资者在做出决定之前应考虑当前的估值。</li></ul><p class=\"t-img-caption\"><span>摄影：Paopano/iStock社论，来自Getty Images</span></p></blockquote></p><p> <b>Article Thesis</b></p><p><blockquote><b>文章论文</b></blockquote></p><p> Apple (AAPL) has been one of the best investments one could have made over the last decade. Over the next decade, its growth may not be the same, however. Yet, thanks to massive shareholder return programs and a move towards services, Apple's stock will likely still be significantly higher a decade from now - even though the current valuation is rather high.</p><p><blockquote>苹果（AAPL）是过去十年中最好的投资之一。然而，在接下来的十年里，它的增长可能会有所不同。然而，由于大规模的股东回报计划和向服务业的转变，苹果的股价在十年后仍可能大幅上涨——尽管目前的估值相当高。</blockquote></p><p> <b>Apple Stock Price</b></p><p><blockquote><b>苹果股价</b></blockquote></p><p> Over the last decade, Apple Inc. has been a great investment:</p><p><blockquote>在过去十年中，苹果公司一直是一项伟大的投资：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d29aa34bdbc5bab7d0730a4095954e6\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares have returned 900% in those ten years, before dividends, for a compounded annual return of approximately 26%, easily trouncing the returns of the broad market during that time frame. Importantly, shares have risen a lot more than the company's market capitalization, which grew by only 550% over the last decade. The difference can be explained by the company's large share repurchase programs, which have lowered the share count drastically over the last decade. The last decade, of course, was a highly successful period for Apple on a business basis, as the company benefited from the rise of smartphones while also having success with new products such as its Watch and tablets, which Apple more or less introduced as a new product category. Right now, shares trade for $125, up 57% over the last twelve months, but down 6% in 2021 to date. Following strong gains during 2020, shares seem to be in a consolidation pattern for now, which is not too much of a surprise, as Apple's valuation had expanded a lot in the recent past, and it seems that the company's business growth has to catch up to the recent share price increases now. The current consensus price target is $156, which implies an upside potential of 25%. Since there are no signs of shares leaving their current trading range right now, I personally do not think that Apple will breach $150 in the near term.</p><p><blockquote>在这十年中，扣除股息前，股票回报率为900%，复合年回报率约为26%，轻松击败了同期大盘的回报率。重要的是，该公司股价的涨幅远远超过了该公司的市值，而该公司的市值在过去十年中仅增长了550%。这种差异可以用该公司的大规模股票回购计划来解释，该计划在过去十年中大幅减少了股票数量。当然，过去十年对苹果来说是一个商业上非常成功的时期，因为该公司受益于智能手机的兴起，同时也在手表和平板电脑等新产品上取得了成功，苹果或多或少地将其作为一个新产品类别推出。目前，股价为125美元，过去12个月上涨57%，但2021年迄今下跌6%。继2020年强劲上涨之后，股价目前似乎处于盘整格局，这并不令人意外，因为苹果的估值最近已经扩大了很多，而且该公司的业务增长似乎必须赶上最近的股价上涨。目前的一致目标价为156美元，这意味着25%的上涨潜力。由于目前没有迹象表明股价会离开当前的交易区间，我个人认为苹果短期内不会突破150美元。</blockquote></p><p> <b>Where Will Apple Stock Be In 10 Years</b></p><p><blockquote><b>10年后苹果股票会在哪里</b></blockquote></p><p> Apple's stock price in 2031 is, of course, nothing that can be forecasted with any precision. As history has shown, again and again, it is not even possible to forecast share prices precisely over a much shorter period of time. It is, however, possible to craft scenarios to see where share prices could be in the future under certain conditions, to get a feel for what might be a reasonable expectation for the future.</p><p><blockquote>当然，苹果2031年的股价是无法准确预测的。正如历史一次又一次地表明的那样，甚至不可能在更短的时间内准确预测股价。然而，可以设计情景来了解在某些条件下未来股价的走势，从而了解对未来的合理预期。</blockquote></p><p> To craft one such scenario, we have to consider Apple's business growth, Apple's shareholder return program, and the valuation multiple that shares might trade at in the future.</p><p><blockquote>为了构建这样的场景，我们必须考虑苹果的业务增长、苹果的股东回报计划以及股票未来可能交易的估值倍数。</blockquote></p><p> <b>Apple's business growth</b></p><p><blockquote><b>苹果的业务增长</b></blockquote></p><p> Apple Inc. has seen years of stronger growth and years of weaker growth in the past. This mostly can be explained by factors such as new product introductions, e.g. Watch or iPad, and by the strength of the respective current iPhone models, which see varying demand depending on the year. Other factors, such as economic growth or trade issues, play a role as well.</p><p><blockquote>苹果公司过去曾经历过多年的强劲增长和多年的疲软增长。这主要可以用新产品推出等因素来解释，例如。手表或iPad，以及各自当前iPhone型号的强度，这些型号的需求因年份而异。其他因素，如经济增长或贸易问题，也发挥了作用。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5b8bd8ef6cdaa13850c1380e870554c\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Overall, revenues have grown by 154% over the last decade, but as we see in the above chart, revenue growth has been relatively uneven. During the early 2010s, Apple generated massive growth on the back of the iPhones \"road to victory\", whereas revenue growth declined to a much slower pace in the following years. There were even some years during which revenues declined on a year-over-year basis, such as 2016. The average annual revenue growth pace was 10% over the last decade, but when we factor in that this was lifted up by the very strong growth in 2011 and 2012, it may not be too reasonable to assume that Apple will grow by 10% a year in the future, too. Investors should also consider that maintaining a high growth rate becomes ever more difficult the larger a company gets. This does, however, not mean that Apple's revenue growth will slow down to zero.</p><p><blockquote>总体而言，过去十年收入增长了154%，但正如我们在上图中看到的，收入增长相对不均衡。2010年代初，苹果凭借iPhone的“胜利之路”实现了巨大增长，而在接下来的几年里，收入增长速度放缓。甚至有一些年份的收入同比下降，例如2016年。过去十年的平均年收入增长率为10%，但当我们考虑到2011年和2012年的强劲增长推动了这一增长率时，假设苹果将增长10%可能不太合理。未来一年也是如此。投资者还应该考虑到，公司规模越大，保持高增长率就变得越困难。然而，这并不意味着苹果的收入增长将放缓至零。</blockquote></p><p></p><p> On the back of price increases for its products and the potential for market share gains in&nbsp;high-growth countries such as China, where more and more people will be able to buy Apple's higher-priced products, it seems reasonable to assume that Apple will generate at least some growth from its core businesses. Add in growth in the services segment - people use their phones more and more, which should lead to higher app spending - and consider the potential for new product launches (although I assume none will be as massive as the iPhone), and Apple should be able to grow its business at a solid pace. I personally assume that a 5%-7% revenue growth rate could be a realistic estimate for the coming years, although some readers will of course have different opinions.</p><p><blockquote>在其产品价格上涨以及中国等高增长国家市场份额增长的潜力（越来越多的人将能够购买苹果价格较高的产品）的背景下，似乎有理由假设苹果将至少从其核心业务中产生一些增长。再加上服务领域的增长——人们越来越多地使用手机，这应该会导致更高的应用支出——并考虑新产品发布的潜力（尽管我认为没有一款产品会像iPhone那样庞大），苹果应该能够以稳健的速度发展其业务。我个人认为5%-7%的收入增长率可能是未来几年的现实估计，尽管一些读者当然会有不同的意见。</blockquote></p><p> <b>Apple's shareholder returns</b></p><p><blockquote><b>苹果的股东回报</b></blockquote></p><p> Apple has lowered its share count massively in the past, as shown above, and it is, I believe, reasonable to assume that the same will happen going forward. Over the last decade, Apple bought back 36% of its shares. If the same were to happen over the next decade, each remaining share's portion of the company's value would rise by 56%, or 4.6% annualized. Due to the fact that Apple's current valuation is significantly higher than its historic valuation, buybacks could be less impactful in the future, though. Apple has, for example, only reduced its share count by 2.6% over the last year.</p><p><blockquote>如上所示，苹果过去曾大幅减少其股票数量，我相信，有理由假设未来也会发生同样的情况。过去十年，苹果回购了36%的股份。如果未来十年发生同样的情况，每股剩余股票在公司价值中的份额将上涨56%，即年化4.6%。不过，由于苹果目前的估值明显高于其历史估值，回购在未来的影响可能会较小。例如，苹果去年的股票数量仅减少了2.6%。</blockquote></p><p> This is why I believe that the share count will not decline by another 36% over the coming decade. When we adjust that downward to 25%, this would result in a ~3% annual tailwind for Apple's growth when we look at per-share metrics, which are the deciding factor for Apple's share price growth. Combined with my 5%-7% business growth estimate, I thus assume that Apple will grow by 8%-10% on a per-share basis in the long term.</p><p><blockquote>这就是为什么我相信未来十年股票数量不会再下降36%。当我们将其向下调整至25%时，当我们考虑每股指标时，这将为苹果的增长带来约3%的年度推动力，而每股指标是苹果股价增长的决定性因素。结合我5%-7%的业务增长预测，我因此假设苹果的每股长期增长将达到8%-10%。</blockquote></p><p> <b>Apple's future valuation</b></p><p><blockquote><b>苹果的未来估值</b></blockquote></p><p> AAPL has been valued in a very wide range in the past, seeing its shares trade for very low multiples at some points, whereas investors were willing to pay significantly more at other times:</p><p><blockquote>苹果公司过去的估值范围很广，其股票在某些时候的市盈率非常低，而投资者在其他时候愿意支付更高的价格：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be5cb8bbc04ff0e0a13ee64f6f2bd90a\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares could, five years ago, be bought for a very low 10x net earnings, which naturally was a great time to enter or expand positions. In late 2020, however, shares were trading for as much as 40x the company's net earnings, which seems like a quite high valuation. Right now, AAPL trades at 28x trailing earnings, and at around 24x forward profits. In the above chart, we also see the median earnings multiples over the last 3, 5, 7, and 10 years. It is pretty clear that Apple's valuation has expanded over the years, which is why the median values are higher for the shorter \"lookback\" periods. I do not believe that AAPL will trade at the 15.5x net earnings that it has traded at, on average, over the last decade, as this seems like a rather low valuation for a quality company like Apple with a strong brand, massive scale, great margins, and a fortress balance sheet. On the other hand, I also don't believe that Apple will trade at a 24-28x earnings multiple forever - for a company that generates solid but unspectacular business growth in the mid-single-digits, that seems quite expensive. This is especially true when we consider that interest rates will likely be higher a decade from now, which should pressure valuations for all equities, all else equal. I thus believe that a valuation of around 20x net earnings could be a reasonable estimate for 2031, which would be more or less in line with the 3-year median earnings multiple.</p><p><blockquote>五年前，可以以非常低的10倍净利润购买股票，这自然是进入或扩大头寸的好时机。然而，2020年底，该公司的股价高达该公司净利润的40倍，这似乎是一个相当高的估值。目前，AAPL的往绩市盈率为28倍，远期利润约为24倍。在上图中，我们还看到了过去3年、5年、7年和10年的市盈率中位数。很明显，苹果的估值多年来一直在扩大，这就是为什么在较短的“回顾”期内中值较高。我不认为AAPL的市盈率会达到过去十年平均市盈率的15.5倍，因为对于像苹果这样拥有强大品牌、庞大规模的优质公司来说，这似乎是一个相当低的估值。、巨大的利润和堡垒般的资产负债表。另一方面，我也不相信苹果的市盈率会永远保持在24-28倍——对于一家业务增长稳健但不引人注目的中个位数的公司来说，这似乎相当昂贵。当我们考虑到十年后利率可能会更高时，尤其如此，在其他条件相同的情况下，这应该会给所有股票的估值带来压力。因此，我认为2031年净利润20倍左右的估值可能是合理的估计，这或多或少与3年市盈率中位数一致。</blockquote></p><p> <b>Is AAPL A Buy Or Sell Now</b></p><p><blockquote><b>AAPL现在是买入还是卖出</b></blockquote></p><p> Starting our calculation with an EPS estimate of $5.15 for 2021 and assuming that this will grow by 7%-10% a year through 2031, we reach an EPS range of $10.10 to $13.40. Putting a 20x earnings multiple on that leads to a target price of around $200-$270/share. At the midpoint of around $235, shares would thus see gains of around 90% from the current level, or around 6.5% annualized. That surely is not a bad return, and when we add in the dividend, we would get to an annualized return of roughly 7%. This is, on the other hand, also not an outrageously great return, I believe.</p><p><blockquote>从2021年每股收益估计为5.15美元开始计算，并假设到2031年每年增长7%-10%，我们的每股收益范围为10.10美元至13.40美元。将市盈率定为20倍，目标价约为每股200-270美元。因此，在235美元左右的中点，股价将较当前水平上涨约90%，年化涨幅约为6.5%。这肯定是一个不错的回报，当我们加上股息时，我们将获得大约7%的年化回报率。另一方面，我相信这也不是一个惊人的回报。</blockquote></p><p></p><p> AAPL has, I believe, significant upside potential over the next decade, but that should not be a large surprise - many companies will see significant growth over a time span this long. I personally am not too excited about a 7% expected long-term return. When we consider that shares do have considerable downside risk in the next 1-3 years if Apple's valuation declines, e.g. due to rising interest rates, it may be a better choice to stay on the sidelines for now. Long-term investors will likely not do badly when they buy shares at current levels, but they will likely also not do great. For now, I'd rate Apple a hold, and a potential buy if its valuation comes closer to the longer-term average. Those that are more optimistic about new product launches may disagree and favor buying here, but it could turn out that waiting for a better opportunity is the best choice here.</p><p><blockquote>我相信，苹果公司在未来十年具有巨大的上涨潜力，但这并不令人意外——许多公司将在这么长的时间内实现显着增长。我个人对7%的预期长期回报率不太兴奋。当我们考虑到，如果苹果的估值下降，例如由于利率上升，股价在未来1-3年内确实存在相当大的下行风险，目前保持观望可能是更好的选择。长期投资者在当前水平购买股票时可能不会表现不佳，但也可能不会表现出色。目前，我对苹果的评级为持有，如果其估值接近长期平均水平，则可能买入。那些对新产品发布更乐观的人可能不同意并倾向于在这里购买，但事实证明，等待更好的机会是这里的最佳选择。</blockquote></p><p> Summing it up, I'd say shares do have significant upside potential over the next decade, but the upside potential is not large enough to make me buy shares at current, elevated, valuations.</p><p><blockquote>总而言之，我想说，该股在未来十年确实有巨大的上涨潜力，但上涨潜力还不足以让我以当前较高的估值购买股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Where Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhere Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-06-04 15:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has been a great investment over the last decade, but the next decade may look quite different.</li>  <li>Apple has seen its growth slow down over the last decade, and it will likely not be a growth monster in the coming years, either.</li>  <li>Shares have ample long-term upside, but investors should consider the current valuation before jumping to decisions.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f2ea192ed76d9772c2c6a820098faf5\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>Photo by Paopano/iStock Editorial via Getty Images</span></p><p><blockquote><ul><li>苹果在过去十年中是一项伟大的投资，但下一个十年可能会大不相同。</li><li>苹果的增长在过去十年中有所放缓，未来几年也可能不会成为增长怪物。</li><li>股价具有充足的长期上涨空间，但投资者在做出决定之前应考虑当前的估值。</li></ul><p class=\"t-img-caption\"><span>摄影：Paopano/iStock社论，来自Getty Images</span></p></blockquote></p><p> <b>Article Thesis</b></p><p><blockquote><b>文章论文</b></blockquote></p><p> Apple (AAPL) has been one of the best investments one could have made over the last decade. Over the next decade, its growth may not be the same, however. Yet, thanks to massive shareholder return programs and a move towards services, Apple's stock will likely still be significantly higher a decade from now - even though the current valuation is rather high.</p><p><blockquote>苹果（AAPL）是过去十年中最好的投资之一。然而，在接下来的十年里，它的增长可能会有所不同。然而，由于大规模的股东回报计划和向服务业的转变，苹果的股价在十年后仍可能大幅上涨——尽管目前的估值相当高。</blockquote></p><p> <b>Apple Stock Price</b></p><p><blockquote><b>苹果股价</b></blockquote></p><p> Over the last decade, Apple Inc. has been a great investment:</p><p><blockquote>在过去十年中，苹果公司一直是一项伟大的投资：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d29aa34bdbc5bab7d0730a4095954e6\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares have returned 900% in those ten years, before dividends, for a compounded annual return of approximately 26%, easily trouncing the returns of the broad market during that time frame. Importantly, shares have risen a lot more than the company's market capitalization, which grew by only 550% over the last decade. The difference can be explained by the company's large share repurchase programs, which have lowered the share count drastically over the last decade. The last decade, of course, was a highly successful period for Apple on a business basis, as the company benefited from the rise of smartphones while also having success with new products such as its Watch and tablets, which Apple more or less introduced as a new product category. Right now, shares trade for $125, up 57% over the last twelve months, but down 6% in 2021 to date. Following strong gains during 2020, shares seem to be in a consolidation pattern for now, which is not too much of a surprise, as Apple's valuation had expanded a lot in the recent past, and it seems that the company's business growth has to catch up to the recent share price increases now. The current consensus price target is $156, which implies an upside potential of 25%. Since there are no signs of shares leaving their current trading range right now, I personally do not think that Apple will breach $150 in the near term.</p><p><blockquote>在这十年中，扣除股息前，股票回报率为900%，复合年回报率约为26%，轻松击败了同期大盘的回报率。重要的是，该公司股价的涨幅远远超过了该公司的市值，而该公司的市值在过去十年中仅增长了550%。这种差异可以用该公司的大规模股票回购计划来解释，该计划在过去十年中大幅减少了股票数量。当然，过去十年对苹果来说是一个商业上非常成功的时期，因为该公司受益于智能手机的兴起，同时也在手表和平板电脑等新产品上取得了成功，苹果或多或少地将其作为一个新产品类别推出。目前，股价为125美元，过去12个月上涨57%，但2021年迄今下跌6%。继2020年强劲上涨之后，股价目前似乎处于盘整格局，这并不令人意外，因为苹果的估值最近已经扩大了很多，而且该公司的业务增长似乎必须赶上最近的股价上涨。目前的一致目标价为156美元，这意味着25%的上涨潜力。由于目前没有迹象表明股价会离开当前的交易区间，我个人认为苹果短期内不会突破150美元。</blockquote></p><p> <b>Where Will Apple Stock Be In 10 Years</b></p><p><blockquote><b>10年后苹果股票会在哪里</b></blockquote></p><p> Apple's stock price in 2031 is, of course, nothing that can be forecasted with any precision. As history has shown, again and again, it is not even possible to forecast share prices precisely over a much shorter period of time. It is, however, possible to craft scenarios to see where share prices could be in the future under certain conditions, to get a feel for what might be a reasonable expectation for the future.</p><p><blockquote>当然，苹果2031年的股价是无法准确预测的。正如历史一次又一次地表明的那样，甚至不可能在更短的时间内准确预测股价。然而，可以设计情景来了解在某些条件下未来股价的走势，从而了解对未来的合理预期。</blockquote></p><p> To craft one such scenario, we have to consider Apple's business growth, Apple's shareholder return program, and the valuation multiple that shares might trade at in the future.</p><p><blockquote>为了构建这样的场景，我们必须考虑苹果的业务增长、苹果的股东回报计划以及股票未来可能交易的估值倍数。</blockquote></p><p> <b>Apple's business growth</b></p><p><blockquote><b>苹果的业务增长</b></blockquote></p><p> Apple Inc. has seen years of stronger growth and years of weaker growth in the past. This mostly can be explained by factors such as new product introductions, e.g. Watch or iPad, and by the strength of the respective current iPhone models, which see varying demand depending on the year. Other factors, such as economic growth or trade issues, play a role as well.</p><p><blockquote>苹果公司过去曾经历过多年的强劲增长和多年的疲软增长。这主要可以用新产品推出等因素来解释，例如。手表或iPad，以及各自当前iPhone型号的强度，这些型号的需求因年份而异。其他因素，如经济增长或贸易问题，也发挥了作用。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5b8bd8ef6cdaa13850c1380e870554c\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Overall, revenues have grown by 154% over the last decade, but as we see in the above chart, revenue growth has been relatively uneven. During the early 2010s, Apple generated massive growth on the back of the iPhones \"road to victory\", whereas revenue growth declined to a much slower pace in the following years. There were even some years during which revenues declined on a year-over-year basis, such as 2016. The average annual revenue growth pace was 10% over the last decade, but when we factor in that this was lifted up by the very strong growth in 2011 and 2012, it may not be too reasonable to assume that Apple will grow by 10% a year in the future, too. Investors should also consider that maintaining a high growth rate becomes ever more difficult the larger a company gets. This does, however, not mean that Apple's revenue growth will slow down to zero.</p><p><blockquote>总体而言，过去十年收入增长了154%，但正如我们在上图中看到的，收入增长相对不均衡。2010年代初，苹果凭借iPhone的“胜利之路”实现了巨大增长，而在接下来的几年里，收入增长速度放缓。甚至有一些年份的收入同比下降，例如2016年。过去十年的平均年收入增长率为10%，但当我们考虑到2011年和2012年的强劲增长推动了这一增长率时，假设苹果将增长10%可能不太合理。未来一年也是如此。投资者还应该考虑到，公司规模越大，保持高增长率就变得越困难。然而，这并不意味着苹果的收入增长将放缓至零。</blockquote></p><p></p><p> On the back of price increases for its products and the potential for market share gains in&nbsp;high-growth countries such as China, where more and more people will be able to buy Apple's higher-priced products, it seems reasonable to assume that Apple will generate at least some growth from its core businesses. Add in growth in the services segment - people use their phones more and more, which should lead to higher app spending - and consider the potential for new product launches (although I assume none will be as massive as the iPhone), and Apple should be able to grow its business at a solid pace. I personally assume that a 5%-7% revenue growth rate could be a realistic estimate for the coming years, although some readers will of course have different opinions.</p><p><blockquote>在其产品价格上涨以及中国等高增长国家市场份额增长的潜力（越来越多的人将能够购买苹果价格较高的产品）的背景下，似乎有理由假设苹果将至少从其核心业务中产生一些增长。再加上服务领域的增长——人们越来越多地使用手机，这应该会导致更高的应用支出——并考虑新产品发布的潜力（尽管我认为没有一款产品会像iPhone那样庞大），苹果应该能够以稳健的速度发展其业务。我个人认为5%-7%的收入增长率可能是未来几年的现实估计，尽管一些读者当然会有不同的意见。</blockquote></p><p> <b>Apple's shareholder returns</b></p><p><blockquote><b>苹果的股东回报</b></blockquote></p><p> Apple has lowered its share count massively in the past, as shown above, and it is, I believe, reasonable to assume that the same will happen going forward. Over the last decade, Apple bought back 36% of its shares. If the same were to happen over the next decade, each remaining share's portion of the company's value would rise by 56%, or 4.6% annualized. Due to the fact that Apple's current valuation is significantly higher than its historic valuation, buybacks could be less impactful in the future, though. Apple has, for example, only reduced its share count by 2.6% over the last year.</p><p><blockquote>如上所示，苹果过去曾大幅减少其股票数量，我相信，有理由假设未来也会发生同样的情况。过去十年，苹果回购了36%的股份。如果未来十年发生同样的情况，每股剩余股票在公司价值中的份额将上涨56%，即年化4.6%。不过，由于苹果目前的估值明显高于其历史估值，回购在未来的影响可能会较小。例如，苹果去年的股票数量仅减少了2.6%。</blockquote></p><p> This is why I believe that the share count will not decline by another 36% over the coming decade. When we adjust that downward to 25%, this would result in a ~3% annual tailwind for Apple's growth when we look at per-share metrics, which are the deciding factor for Apple's share price growth. Combined with my 5%-7% business growth estimate, I thus assume that Apple will grow by 8%-10% on a per-share basis in the long term.</p><p><blockquote>这就是为什么我相信未来十年股票数量不会再下降36%。当我们将其向下调整至25%时，当我们考虑每股指标时，这将为苹果的增长带来约3%的年度推动力，而每股指标是苹果股价增长的决定性因素。结合我5%-7%的业务增长预测，我因此假设苹果的每股长期增长将达到8%-10%。</blockquote></p><p> <b>Apple's future valuation</b></p><p><blockquote><b>苹果的未来估值</b></blockquote></p><p> AAPL has been valued in a very wide range in the past, seeing its shares trade for very low multiples at some points, whereas investors were willing to pay significantly more at other times:</p><p><blockquote>苹果公司过去的估值范围很广，其股票在某些时候的市盈率非常低，而投资者在其他时候愿意支付更高的价格：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be5cb8bbc04ff0e0a13ee64f6f2bd90a\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares could, five years ago, be bought for a very low 10x net earnings, which naturally was a great time to enter or expand positions. In late 2020, however, shares were trading for as much as 40x the company's net earnings, which seems like a quite high valuation. Right now, AAPL trades at 28x trailing earnings, and at around 24x forward profits. In the above chart, we also see the median earnings multiples over the last 3, 5, 7, and 10 years. It is pretty clear that Apple's valuation has expanded over the years, which is why the median values are higher for the shorter \"lookback\" periods. I do not believe that AAPL will trade at the 15.5x net earnings that it has traded at, on average, over the last decade, as this seems like a rather low valuation for a quality company like Apple with a strong brand, massive scale, great margins, and a fortress balance sheet. On the other hand, I also don't believe that Apple will trade at a 24-28x earnings multiple forever - for a company that generates solid but unspectacular business growth in the mid-single-digits, that seems quite expensive. This is especially true when we consider that interest rates will likely be higher a decade from now, which should pressure valuations for all equities, all else equal. I thus believe that a valuation of around 20x net earnings could be a reasonable estimate for 2031, which would be more or less in line with the 3-year median earnings multiple.</p><p><blockquote>五年前，可以以非常低的10倍净利润购买股票，这自然是进入或扩大头寸的好时机。然而，2020年底，该公司的股价高达该公司净利润的40倍，这似乎是一个相当高的估值。目前，AAPL的往绩市盈率为28倍，远期利润约为24倍。在上图中，我们还看到了过去3年、5年、7年和10年的市盈率中位数。很明显，苹果的估值多年来一直在扩大，这就是为什么在较短的“回顾”期内中值较高。我不认为AAPL的市盈率会达到过去十年平均市盈率的15.5倍，因为对于像苹果这样拥有强大品牌、庞大规模的优质公司来说，这似乎是一个相当低的估值。、巨大的利润和堡垒般的资产负债表。另一方面，我也不相信苹果的市盈率会永远保持在24-28倍——对于一家业务增长稳健但不引人注目的中个位数的公司来说，这似乎相当昂贵。当我们考虑到十年后利率可能会更高时，尤其如此，在其他条件相同的情况下，这应该会给所有股票的估值带来压力。因此，我认为2031年净利润20倍左右的估值可能是合理的估计，这或多或少与3年市盈率中位数一致。</blockquote></p><p> <b>Is AAPL A Buy Or Sell Now</b></p><p><blockquote><b>AAPL现在是买入还是卖出</b></blockquote></p><p> Starting our calculation with an EPS estimate of $5.15 for 2021 and assuming that this will grow by 7%-10% a year through 2031, we reach an EPS range of $10.10 to $13.40. Putting a 20x earnings multiple on that leads to a target price of around $200-$270/share. At the midpoint of around $235, shares would thus see gains of around 90% from the current level, or around 6.5% annualized. That surely is not a bad return, and when we add in the dividend, we would get to an annualized return of roughly 7%. This is, on the other hand, also not an outrageously great return, I believe.</p><p><blockquote>从2021年每股收益估计为5.15美元开始计算，并假设到2031年每年增长7%-10%，我们的每股收益范围为10.10美元至13.40美元。将市盈率定为20倍，目标价约为每股200-270美元。因此，在235美元左右的中点，股价将较当前水平上涨约90%，年化涨幅约为6.5%。这肯定是一个不错的回报，当我们加上股息时，我们将获得大约7%的年化回报率。另一方面，我相信这也不是一个惊人的回报。</blockquote></p><p></p><p> AAPL has, I believe, significant upside potential over the next decade, but that should not be a large surprise - many companies will see significant growth over a time span this long. I personally am not too excited about a 7% expected long-term return. When we consider that shares do have considerable downside risk in the next 1-3 years if Apple's valuation declines, e.g. due to rising interest rates, it may be a better choice to stay on the sidelines for now. Long-term investors will likely not do badly when they buy shares at current levels, but they will likely also not do great. For now, I'd rate Apple a hold, and a potential buy if its valuation comes closer to the longer-term average. Those that are more optimistic about new product launches may disagree and favor buying here, but it could turn out that waiting for a better opportunity is the best choice here.</p><p><blockquote>我相信，苹果公司在未来十年具有巨大的上涨潜力，但这并不令人意外——许多公司将在这么长的时间内实现显着增长。我个人对7%的预期长期回报率不太兴奋。当我们考虑到，如果苹果的估值下降，例如由于利率上升，股价在未来1-3年内确实存在相当大的下行风险，目前保持观望可能是更好的选择。长期投资者在当前水平购买股票时可能不会表现不佳，但也可能不会表现出色。目前，我对苹果的评级为持有，如果其估值接近长期平均水平，则可能买入。那些对新产品发布更乐观的人可能不同意并倾向于在这里购买，但事实证明，等待更好的机会是这里的最佳选择。</blockquote></p><p> Summing it up, I'd say shares do have significant upside potential over the next decade, but the upside potential is not large enough to make me buy shares at current, elevated, valuations.</p><p><blockquote>总而言之，我想说，该股在未来十年确实有巨大的上涨潜力，但上涨潜力还不足以让我以当前较高的估值购买股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4432703-apple-stock-in-10-years\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4432703-apple-stock-in-10-years","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122373606","content_text":"Summary\n\nApple has been a great investment over the last decade, but the next decade may look quite different.\nApple has seen its growth slow down over the last decade, and it will likely not be a growth monster in the coming years, either.\nShares have ample long-term upside, but investors should consider the current valuation before jumping to decisions.\n\nPhoto by Paopano/iStock Editorial via Getty Images\nArticle Thesis\nApple (AAPL) has been one of the best investments one could have made over the last decade. Over the next decade, its growth may not be the same, however. Yet, thanks to massive shareholder return programs and a move towards services, Apple's stock will likely still be significantly higher a decade from now - even though the current valuation is rather high.\nApple Stock Price\nOver the last decade, Apple Inc. has been a great investment:\nData by YCharts\nShares have returned 900% in those ten years, before dividends, for a compounded annual return of approximately 26%, easily trouncing the returns of the broad market during that time frame. Importantly, shares have risen a lot more than the company's market capitalization, which grew by only 550% over the last decade. The difference can be explained by the company's large share repurchase programs, which have lowered the share count drastically over the last decade. The last decade, of course, was a highly successful period for Apple on a business basis, as the company benefited from the rise of smartphones while also having success with new products such as its Watch and tablets, which Apple more or less introduced as a new product category. Right now, shares trade for $125, up 57% over the last twelve months, but down 6% in 2021 to date. Following strong gains during 2020, shares seem to be in a consolidation pattern for now, which is not too much of a surprise, as Apple's valuation had expanded a lot in the recent past, and it seems that the company's business growth has to catch up to the recent share price increases now. The current consensus price target is $156, which implies an upside potential of 25%. Since there are no signs of shares leaving their current trading range right now, I personally do not think that Apple will breach $150 in the near term.\nWhere Will Apple Stock Be In 10 Years\nApple's stock price in 2031 is, of course, nothing that can be forecasted with any precision. As history has shown, again and again, it is not even possible to forecast share prices precisely over a much shorter period of time. It is, however, possible to craft scenarios to see where share prices could be in the future under certain conditions, to get a feel for what might be a reasonable expectation for the future.\nTo craft one such scenario, we have to consider Apple's business growth, Apple's shareholder return program, and the valuation multiple that shares might trade at in the future.\nApple's business growth\nApple Inc. has seen years of stronger growth and years of weaker growth in the past. This mostly can be explained by factors such as new product introductions, e.g. Watch or iPad, and by the strength of the respective current iPhone models, which see varying demand depending on the year. Other factors, such as economic growth or trade issues, play a role as well.\nData by YCharts\nOverall, revenues have grown by 154% over the last decade, but as we see in the above chart, revenue growth has been relatively uneven. During the early 2010s, Apple generated massive growth on the back of the iPhones \"road to victory\", whereas revenue growth declined to a much slower pace in the following years. There were even some years during which revenues declined on a year-over-year basis, such as 2016. The average annual revenue growth pace was 10% over the last decade, but when we factor in that this was lifted up by the very strong growth in 2011 and 2012, it may not be too reasonable to assume that Apple will grow by 10% a year in the future, too. Investors should also consider that maintaining a high growth rate becomes ever more difficult the larger a company gets. This does, however, not mean that Apple's revenue growth will slow down to zero.\nOn the back of price increases for its products and the potential for market share gains in high-growth countries such as China, where more and more people will be able to buy Apple's higher-priced products, it seems reasonable to assume that Apple will generate at least some growth from its core businesses. Add in growth in the services segment - people use their phones more and more, which should lead to higher app spending - and consider the potential for new product launches (although I assume none will be as massive as the iPhone), and Apple should be able to grow its business at a solid pace. I personally assume that a 5%-7% revenue growth rate could be a realistic estimate for the coming years, although some readers will of course have different opinions.\nApple's shareholder returns\nApple has lowered its share count massively in the past, as shown above, and it is, I believe, reasonable to assume that the same will happen going forward. Over the last decade, Apple bought back 36% of its shares. If the same were to happen over the next decade, each remaining share's portion of the company's value would rise by 56%, or 4.6% annualized. Due to the fact that Apple's current valuation is significantly higher than its historic valuation, buybacks could be less impactful in the future, though. Apple has, for example, only reduced its share count by 2.6% over the last year.\nThis is why I believe that the share count will not decline by another 36% over the coming decade. When we adjust that downward to 25%, this would result in a ~3% annual tailwind for Apple's growth when we look at per-share metrics, which are the deciding factor for Apple's share price growth. Combined with my 5%-7% business growth estimate, I thus assume that Apple will grow by 8%-10% on a per-share basis in the long term.\nApple's future valuation\nAAPL has been valued in a very wide range in the past, seeing its shares trade for very low multiples at some points, whereas investors were willing to pay significantly more at other times:\nData by YCharts\nShares could, five years ago, be bought for a very low 10x net earnings, which naturally was a great time to enter or expand positions. In late 2020, however, shares were trading for as much as 40x the company's net earnings, which seems like a quite high valuation. Right now, AAPL trades at 28x trailing earnings, and at around 24x forward profits. In the above chart, we also see the median earnings multiples over the last 3, 5, 7, and 10 years. It is pretty clear that Apple's valuation has expanded over the years, which is why the median values are higher for the shorter \"lookback\" periods. I do not believe that AAPL will trade at the 15.5x net earnings that it has traded at, on average, over the last decade, as this seems like a rather low valuation for a quality company like Apple with a strong brand, massive scale, great margins, and a fortress balance sheet. On the other hand, I also don't believe that Apple will trade at a 24-28x earnings multiple forever - for a company that generates solid but unspectacular business growth in the mid-single-digits, that seems quite expensive. This is especially true when we consider that interest rates will likely be higher a decade from now, which should pressure valuations for all equities, all else equal. I thus believe that a valuation of around 20x net earnings could be a reasonable estimate for 2031, which would be more or less in line with the 3-year median earnings multiple.\nIs AAPL A Buy Or Sell Now\nStarting our calculation with an EPS estimate of $5.15 for 2021 and assuming that this will grow by 7%-10% a year through 2031, we reach an EPS range of $10.10 to $13.40. Putting a 20x earnings multiple on that leads to a target price of around $200-$270/share. At the midpoint of around $235, shares would thus see gains of around 90% from the current level, or around 6.5% annualized. That surely is not a bad return, and when we add in the dividend, we would get to an annualized return of roughly 7%. This is, on the other hand, also not an outrageously great return, I believe.\nAAPL has, I believe, significant upside potential over the next decade, but that should not be a large surprise - many companies will see significant growth over a time span this long. I personally am not too excited about a 7% expected long-term return. When we consider that shares do have considerable downside risk in the next 1-3 years if Apple's valuation declines, e.g. due to rising interest rates, it may be a better choice to stay on the sidelines for now. Long-term investors will likely not do badly when they buy shares at current levels, but they will likely also not do great. For now, I'd rate Apple a hold, and a potential buy if its valuation comes closer to the longer-term average. Those that are more optimistic about new product launches may disagree and favor buying here, but it could turn out that waiting for a better opportunity is the best choice here.\nSumming it up, I'd say shares do have significant upside potential over the next decade, but the upside potential is not large enough to make me buy shares at current, elevated, valuations.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3930,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111764866,"gmtCreate":1622700937655,"gmtModify":1634098990248,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Incredible","listText":"Incredible","text":"Incredible","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111764866","repostId":"1115876867","repostType":4,"isVote":1,"tweetType":1,"viewCount":1373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382016755,"gmtCreate":1613301350077,"gmtModify":1634553975668,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Great to know","listText":"Great to know","text":"Great to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382016755","repostId":"2110026963","repostType":4,"isVote":1,"tweetType":1,"viewCount":2935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":388212945,"gmtCreate":1613057354887,"gmtModify":1703769006106,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Interesting findings&nbsp;","listText":"Interesting findings&nbsp;","text":"Interesting findings","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/388212945","repostId":"2110046043","repostType":4,"isVote":1,"tweetType":1,"viewCount":648,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":388218609,"gmtCreate":1613057287501,"gmtModify":1703769004037,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Scary","listText":"Scary","text":"Scary","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/388218609","repostId":"2110046043","repostType":4,"isVote":1,"tweetType":1,"viewCount":668,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":381575210,"gmtCreate":1612972669730,"gmtModify":1703767869254,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Interesting !","listText":"Interesting !","text":"Interesting !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/381575210","repostId":"2110098829","repostType":4,"repost":{"id":"2110098829","kind":"highlight","pubTimestamp":1612942404,"share":"https://www.laohu8.com/m/news/2110098829?lang=zh_CN&edition=full","pubTime":"2021-02-10 15:33","market":"fut","language":"en","title":"Why did Tesla buy bitcoin?<blockquote>特斯拉为什么要收购比特币？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2110098829","media":"MarketWatch","summary":"Tesla Inc. has become the latest major corporation to make an investment in bitcoin, underscoring the increasing acceptability of the digital asset.The big question observers are asking is, why is the Elon Musk-run company doing this?Monday, electric-car maker Tesla said in a public filing that it purchased $1.5 billion of bitcoin and that it expects to begin accepting payment in the cryptocurrency for its products in the future.The move by Tesla to invest in bitcoins was seen as further confirm","content":"<p>Tesla Inc. has become the latest major corporation to make an investment in bitcoin, underscoring the increasing acceptability of the digital asset.</p><p><blockquote>特斯拉公司成为最新一家投资比特币的大公司，突显出这种数字资产的接受度越来越高。</blockquote></p><p> The big question observers are asking is, why is the Elon Musk-run company doing this?</p><p><blockquote>观察家们问的一个大问题是，埃隆·马斯克经营的公司为什么要这样做？</blockquote></p><p> Monday, electric-car maker&nbsp;Tesla&nbsp;said in&nbsp;a&nbsp;public filing&nbsp;that it purchased $1.5 billion of bitcoin&nbsp;and that it expects to begin accepting payment in the cryptocurrency for its products in the future.</p><p><blockquote>周一，电动汽车制造商特斯拉在一份公开文件中表示，它购买了15亿美元的比特币，并预计未来将开始接受其产品的加密货币支付。</blockquote></p><p> The move by Tesla to invest in bitcoins was seen as further confirmation of the legitimacy of the nascent asset that didn’t exist until about 12 years ago.</p><p><blockquote>特斯拉投资比特币的举动被视为进一步证实了这种新兴资产的合法性，这种资产直到大约12年前才存在。</blockquote></p><p> However, bitcoin is seen as a volatile asset that is prone to sharp price volatility and Monday’s announcement by Tesla was described by some&nbsp;corporate finance professionals&nbsp;as an unnecessary addition of risk to the vehicle maker’s balance sheet in the form of currency or a commodity, depending on how you classify bitcoin.</p><p><blockquote>然而，比特币被视为一种波动性资产，容易出现价格剧烈波动，一些企业财务专业人士将特斯拉周一的声明描述为以货币或商品形式给汽车制造商的资产负债表增加了不必要的风险，取决于您如何对比特币进行分类。</blockquote></p><p> While it’s not clear, at this point, why Musk &amp; Co. have opted to expose the company to the possible risk of owning bitcoin, here are a few reasons why the revolutionary company may have aligned itself with the crypto crowd.</p><p><blockquote>虽然目前尚不清楚为什么Musk&amp;Co.选择让该公司面临拥有比特币的可能风险，但以下是这家革命性公司可能与加密货币人群结盟的一些原因。</blockquote></p><p> <b>Diversification</b></p><p><blockquote><b>多元化</b></blockquote></p><p> Tesla made it clear in its statement filed with its regulator the Securities and Exchange Commission that it sees bitcoin as a chance to diversify its cash and cash-equivalent holdings.</p><p><blockquote>特斯拉在向其监管机构美国证券交易委员会提交的声明中明确表示，它将比特币视为实现现金和现金等价物持有多元化的机会。</blockquote></p><p> Corporations usually hold excess cash and/or cash-equivalents, like Treasury bills or commercial paper on their books to provide operational liquidity and generate returns while limiting risks.</p><p><blockquote>公司通常持有多余的现金和/或现金等价物，如国库券或商业票据，以提供运营流动性并在限制风险的同时产生回报。</blockquote></p><p> Tesla wrote, “we updated our investment policy to provide us with more flexibility to further diversify and maximize returns on our cash that is not required to maintain adequate operating liquidity.”</p><p><blockquote>特斯拉写道，“我们更新了投资政策，为我们提供了更大的灵活性，以进一步实现现金回报的多元化和最大化，而这并不是维持充足运营流动性所必需的。”</blockquote></p><p> The move isn’t without risk, Tesla acknowledges as the price of bitcoin could slump.</p><p><blockquote>特斯拉承认，此举并非没有风险，因为比特币的价格可能会暴跌。</blockquote></p><p> “If we hold digital assets and their values decrease relative to our purchase prices, our financial condition may be harmed,” the company acknowledges.</p><p><blockquote>该公司承认：“如果我们持有数字资产，其价值相对于我们的购买价格下降，我们的财务状况可能会受到损害。”</blockquote></p><p> But a single bitcoin, which has soared 62% so far this year, could easily be headed for a six-digit value if bullish momentum continues to build, which would make Musk look smart.</p><p><blockquote>但今年迄今已飙升62%的单一比特币，如果看涨势头继续增强，很容易达到六位数的价值，这将使马斯克看起来很聪明。</blockquote></p><p> <b>Publicity stunt?</b></p><p><blockquote><b>宣传噱头？</b></blockquote></p><p> “Thankfully, Elon Musk on Monday once again ensured no one would be bored, with the unexpected announcement that Tesla will buy&nbsp;bitcoin&nbsp;and accept them as payment for vehicles,” writes Craig Erlam, senior market analyst at Oanda, in a Tuesday research note.</p><p><blockquote>Oanda高级市场分析师Craig Erlam在周二的一份研究报告中写道：“值得庆幸的是，Elon Musk周一再次确保没有人会感到无聊，他出人意料地宣布特斯拉将收购比特币并接受它们作为车辆付款。”</blockquote></p><p> The analyst referred to the move as a “publicity stunt,” a move that everbody is talking about, but there are a number of ways to think about it.</p><p><blockquote>这位分析师将此举称为“宣传噱头”，每个人都在谈论这一举措，但有多种思考方式。</blockquote></p><p> <b>Brand management</b></p><p><blockquote><b>品牌管理</b></blockquote></p><p> Bitcoin is associated with a group of iconoclastic founders who were attempting to break the mold on payments and fiat money. That was the idea behind cryptos being written into code back in 2009 by a person or persons known as Satoshi Nakamoto.</p><p><blockquote>比特币与一群打破传统的创始人有联系，他们试图打破支付和法定货币的模式。这就是2009年中本聪(Satoshi Nakamoto)将密码写入代码背后的想法。</blockquote></p><p> Those rebellious notions align somewhat with Musk’s own agenda of disruption. Tesla is making electric-powered vehicles in a world that has thus far been dominated by fossil-fuel driven cars.</p><p><blockquote>这些叛逆的想法在某种程度上符合马斯克自己的颠覆议程。特斯拉正在一个迄今为止由化石燃料驱动的汽车主导的世界中制造电动汽车。</blockquote></p><p> Moreover, Tesla’s direct-to-customer sales model also is viewed as trendsetting, since many companies sell their cars through unaffiliated dealerships.</p><p><blockquote>此外，特斯拉的直接面向客户的销售模式也被视为引领潮流，因为许多公司通过非附属经销商销售汽车。</blockquote></p><p> Bitcoin’s image as a decentralized asset, not controlled by any one body, also fits with Tesla’s image and that of its leader Musk.</p><p><blockquote>比特币作为一个去中心化资产的形象，不受任何一个机构的控制，也符合特斯拉及其领导人马斯克的形象。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/33c354045da9bf1b0b8bbe93d0eb9e43\" tg-width=\"947\" tg-height=\"673\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>The future of $</b></p><p><blockquote><b>$的未来</b></blockquote></p><p> Tesla’s $1.5 billion investment in bitcoin could also be a simple hedge against the hegemony of the U.S. dollar as the world’s reserve currency since World War Two.</p><p><blockquote>特斯拉在比特币的15亿美元投资也可能是对美元自二战以来作为世界储备货币的霸权的简单对冲。</blockquote></p><p> Bitcoin, or something like it, represents the future of payment systems to many supporters, even if it isn’t currently an effective means of exchange due to its current volatility.</p><p><blockquote>对于许多支持者来说，比特币或类似的东西代表了支付系统的未来，即使由于当前的波动性，它目前还不是一种有效的交换手段。</blockquote></p><p> “Yesterday’s move by Tesla to invest in&nbsp;bitcoin&nbsp;and start accepting it as payment for its own products really moved the needle,” wrote Simon Peters, cryptoasset analyst at multiasset investment platform eToro, in emailed comments.</p><p><blockquote>多资产投资平台eToro的加密资产分析师Simon Peters在电子邮件评论中写道：“特斯拉昨天投资比特币并开始接受其作为自己产品的付款，这确实起到了推动作用。”</blockquote></p><p> The eToro analyst said that there are unconfirmed talks about technology behemoths Apple Inc.&nbsp;and Google-parent Alphabet Inc.,linking it to their own payment systems.</p><p><blockquote>这位eToro分析师表示，有未经证实的传言称科技巨头苹果公司和谷歌母公司Alphabet公司将其与自己的支付系统联系起来。</blockquote></p><p> Musk is viewed as an innovator tied to electric vehicles, batteries and space exploration via SpaceX, but one of his early ventures was in payments.</p><p><blockquote>马斯克被视为通过SpaceX与电动汽车、电池和太空探索相关的创新者，但他早期的投资之一是支付领域。</blockquote></p><p> <b>Writing on the wall</b></p><p><blockquote><b>写在墙上</b></blockquote></p><p> The&nbsp;Wall Street Journal notes&nbsp;that, the Tesla CEO invested most of the $22 million he earned from the sale of an internet business into a new startup, X.com, which became PayPal Holdings&nbsp;about 20 years ago.</p><p><blockquote>《华尔街日报》指出，这位特斯拉首席执行官将出售互联网业务获得的2200万美元中的大部分投资于一家新初创公司X.com，该公司大约20年前成为PayPal控股公司。</blockquote></p><p></p><p> PayPal currently is among the vanguard of bitcoin revolution. PayPal&nbsp;back in November opened up its cryptocurrency platform to all U.S. customers after conducting a more narrow rollout.</p><p><blockquote>PayPal目前是比特币革命的先锋之一。PayPal早在11月就向所有美国客户开放了其加密货币平台，此前该平台进行了较窄的推广。</blockquote></p><p> Moreover, several high-profile Wall Street investors, including Stanley Druckenmiller and Paul Tudor Jones, have embraced bitcoin. Famed investor Bill Miller, founder of Miller Value Partners, in&nbsp;a letter to clients&nbsp;earlier this month&nbsp;published on the firm’s website, reaffirmed his bullish outlook on bitcoin.</p><p><blockquote>此外，包括Stanley Druckenmiller和Paul Tudor Jones在内的几位知名华尔街投资者已经接受了比特币。Miller Value Partners创始人、著名投资者Bill Miller本月早些时候在该公司网站上发表的一封致客户的信中重申了他对比特币的看涨前景。</blockquote></p><p> In other words, Tesla and Musk may be among the biggest to wade into the crypto pool, but a growing cadre of investors are starting to view the volatile digital-ledger-backed cryptos as a bona fide asset.</p><p><blockquote>换句话说，特斯拉和马斯克可能是涉足加密货币领域最大的公司之一，但越来越多的投资者开始将不稳定的数字账本支持的加密货币视为真正的资产。</blockquote></p><p> “Corporate adoption takes another leap forward with Tesla announcement,” writes Devin Ryan, analyst at JMP Securities in a Monday research note.</p><p><blockquote>JMP Securities分析师Devin Ryan在周一的研究报告中写道：“随着特斯拉的宣布，企业采用率又向前迈出了一大步。”</blockquote></p><p> The researcher, along with fellow analyst Brian McKenna, noted they “believe the building ‘network effect’ around bitcoin is moving the broader crypto asset class into the mainstream, and with many hundreds of billions of dollars of value in infrastructure supporting the asset class, we see the already substantial (and growing) vested interest in its success as bullish for the industry.”</p><p><blockquote>该研究人员和分析师同事Brian McKenna指出，他们“相信围绕比特币构建的‘网络效应’正在将更广泛的加密资产类别推向主流，并且价值数千亿美元的基础设施支持该资产类别，我们认为其成功中已经存在的大量（且不断增长）既得利益对该行业有利。”</blockquote></p><p> On Tuesday, bitcoin touched a record high around $48,000 before pulling back, as the Dow Jones Industrial Average,the S&amp;P 500&nbsp;and the Nasdaq Composite&nbsp;indexes have seen relatively tepid trade on the day.</p><p><blockquote>周二，比特币触及48,000美元左右的历史新高，随后回落，道琼斯工业平均指数、标普500和纳斯达克综合指数当天交易相对不温不火。</blockquote></p><p></p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why did Tesla buy bitcoin?<blockquote>特斯拉为什么要收购比特币？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy did Tesla buy bitcoin?<blockquote>特斯拉为什么要收购比特币？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MarketWatch</strong><span class=\"h-time small\">2021-02-10 15:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Tesla Inc. has become the latest major corporation to make an investment in bitcoin, underscoring the increasing acceptability of the digital asset.</p><p><blockquote>特斯拉公司成为最新一家投资比特币的大公司，突显出这种数字资产的接受度越来越高。</blockquote></p><p> The big question observers are asking is, why is the Elon Musk-run company doing this?</p><p><blockquote>观察家们问的一个大问题是，埃隆·马斯克经营的公司为什么要这样做？</blockquote></p><p> Monday, electric-car maker&nbsp;Tesla&nbsp;said in&nbsp;a&nbsp;public filing&nbsp;that it purchased $1.5 billion of bitcoin&nbsp;and that it expects to begin accepting payment in the cryptocurrency for its products in the future.</p><p><blockquote>周一，电动汽车制造商特斯拉在一份公开文件中表示，它购买了15亿美元的比特币，并预计未来将开始接受其产品的加密货币支付。</blockquote></p><p> The move by Tesla to invest in bitcoins was seen as further confirmation of the legitimacy of the nascent asset that didn’t exist until about 12 years ago.</p><p><blockquote>特斯拉投资比特币的举动被视为进一步证实了这种新兴资产的合法性，这种资产直到大约12年前才存在。</blockquote></p><p> However, bitcoin is seen as a volatile asset that is prone to sharp price volatility and Monday’s announcement by Tesla was described by some&nbsp;corporate finance professionals&nbsp;as an unnecessary addition of risk to the vehicle maker’s balance sheet in the form of currency or a commodity, depending on how you classify bitcoin.</p><p><blockquote>然而，比特币被视为一种波动性资产，容易出现价格剧烈波动，一些企业财务专业人士将特斯拉周一的声明描述为以货币或商品形式给汽车制造商的资产负债表增加了不必要的风险，取决于您如何对比特币进行分类。</blockquote></p><p> While it’s not clear, at this point, why Musk &amp; Co. have opted to expose the company to the possible risk of owning bitcoin, here are a few reasons why the revolutionary company may have aligned itself with the crypto crowd.</p><p><blockquote>虽然目前尚不清楚为什么Musk&amp;Co.选择让该公司面临拥有比特币的可能风险，但以下是这家革命性公司可能与加密货币人群结盟的一些原因。</blockquote></p><p> <b>Diversification</b></p><p><blockquote><b>多元化</b></blockquote></p><p> Tesla made it clear in its statement filed with its regulator the Securities and Exchange Commission that it sees bitcoin as a chance to diversify its cash and cash-equivalent holdings.</p><p><blockquote>特斯拉在向其监管机构美国证券交易委员会提交的声明中明确表示，它将比特币视为实现现金和现金等价物持有多元化的机会。</blockquote></p><p> Corporations usually hold excess cash and/or cash-equivalents, like Treasury bills or commercial paper on their books to provide operational liquidity and generate returns while limiting risks.</p><p><blockquote>公司通常持有多余的现金和/或现金等价物，如国库券或商业票据，以提供运营流动性并在限制风险的同时产生回报。</blockquote></p><p> Tesla wrote, “we updated our investment policy to provide us with more flexibility to further diversify and maximize returns on our cash that is not required to maintain adequate operating liquidity.”</p><p><blockquote>特斯拉写道，“我们更新了投资政策，为我们提供了更大的灵活性，以进一步实现现金回报的多元化和最大化，而这并不是维持充足运营流动性所必需的。”</blockquote></p><p> The move isn’t without risk, Tesla acknowledges as the price of bitcoin could slump.</p><p><blockquote>特斯拉承认，此举并非没有风险，因为比特币的价格可能会暴跌。</blockquote></p><p> “If we hold digital assets and their values decrease relative to our purchase prices, our financial condition may be harmed,” the company acknowledges.</p><p><blockquote>该公司承认：“如果我们持有数字资产，其价值相对于我们的购买价格下降，我们的财务状况可能会受到损害。”</blockquote></p><p> But a single bitcoin, which has soared 62% so far this year, could easily be headed for a six-digit value if bullish momentum continues to build, which would make Musk look smart.</p><p><blockquote>但今年迄今已飙升62%的单一比特币，如果看涨势头继续增强，很容易达到六位数的价值，这将使马斯克看起来很聪明。</blockquote></p><p> <b>Publicity stunt?</b></p><p><blockquote><b>宣传噱头？</b></blockquote></p><p> “Thankfully, Elon Musk on Monday once again ensured no one would be bored, with the unexpected announcement that Tesla will buy&nbsp;bitcoin&nbsp;and accept them as payment for vehicles,” writes Craig Erlam, senior market analyst at Oanda, in a Tuesday research note.</p><p><blockquote>Oanda高级市场分析师Craig Erlam在周二的一份研究报告中写道：“值得庆幸的是，Elon Musk周一再次确保没有人会感到无聊，他出人意料地宣布特斯拉将收购比特币并接受它们作为车辆付款。”</blockquote></p><p> The analyst referred to the move as a “publicity stunt,” a move that everbody is talking about, but there are a number of ways to think about it.</p><p><blockquote>这位分析师将此举称为“宣传噱头”，每个人都在谈论这一举措，但有多种思考方式。</blockquote></p><p> <b>Brand management</b></p><p><blockquote><b>品牌管理</b></blockquote></p><p> Bitcoin is associated with a group of iconoclastic founders who were attempting to break the mold on payments and fiat money. That was the idea behind cryptos being written into code back in 2009 by a person or persons known as Satoshi Nakamoto.</p><p><blockquote>比特币与一群打破传统的创始人有联系，他们试图打破支付和法定货币的模式。这就是2009年中本聪(Satoshi Nakamoto)将密码写入代码背后的想法。</blockquote></p><p> Those rebellious notions align somewhat with Musk’s own agenda of disruption. Tesla is making electric-powered vehicles in a world that has thus far been dominated by fossil-fuel driven cars.</p><p><blockquote>这些叛逆的想法在某种程度上符合马斯克自己的颠覆议程。特斯拉正在一个迄今为止由化石燃料驱动的汽车主导的世界中制造电动汽车。</blockquote></p><p> Moreover, Tesla’s direct-to-customer sales model also is viewed as trendsetting, since many companies sell their cars through unaffiliated dealerships.</p><p><blockquote>此外，特斯拉的直接面向客户的销售模式也被视为引领潮流，因为许多公司通过非附属经销商销售汽车。</blockquote></p><p> Bitcoin’s image as a decentralized asset, not controlled by any one body, also fits with Tesla’s image and that of its leader Musk.</p><p><blockquote>比特币作为一个去中心化资产的形象，不受任何一个机构的控制，也符合特斯拉及其领导人马斯克的形象。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/33c354045da9bf1b0b8bbe93d0eb9e43\" tg-width=\"947\" tg-height=\"673\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>The future of $</b></p><p><blockquote><b>$的未来</b></blockquote></p><p> Tesla’s $1.5 billion investment in bitcoin could also be a simple hedge against the hegemony of the U.S. dollar as the world’s reserve currency since World War Two.</p><p><blockquote>特斯拉在比特币的15亿美元投资也可能是对美元自二战以来作为世界储备货币的霸权的简单对冲。</blockquote></p><p> Bitcoin, or something like it, represents the future of payment systems to many supporters, even if it isn’t currently an effective means of exchange due to its current volatility.</p><p><blockquote>对于许多支持者来说，比特币或类似的东西代表了支付系统的未来，即使由于当前的波动性，它目前还不是一种有效的交换手段。</blockquote></p><p> “Yesterday’s move by Tesla to invest in&nbsp;bitcoin&nbsp;and start accepting it as payment for its own products really moved the needle,” wrote Simon Peters, cryptoasset analyst at multiasset investment platform eToro, in emailed comments.</p><p><blockquote>多资产投资平台eToro的加密资产分析师Simon Peters在电子邮件评论中写道：“特斯拉昨天投资比特币并开始接受其作为自己产品的付款，这确实起到了推动作用。”</blockquote></p><p> The eToro analyst said that there are unconfirmed talks about technology behemoths Apple Inc.&nbsp;and Google-parent Alphabet Inc.,linking it to their own payment systems.</p><p><blockquote>这位eToro分析师表示，有未经证实的传言称科技巨头苹果公司和谷歌母公司Alphabet公司将其与自己的支付系统联系起来。</blockquote></p><p> Musk is viewed as an innovator tied to electric vehicles, batteries and space exploration via SpaceX, but one of his early ventures was in payments.</p><p><blockquote>马斯克被视为通过SpaceX与电动汽车、电池和太空探索相关的创新者，但他早期的投资之一是支付领域。</blockquote></p><p> <b>Writing on the wall</b></p><p><blockquote><b>写在墙上</b></blockquote></p><p> The&nbsp;Wall Street Journal notes&nbsp;that, the Tesla CEO invested most of the $22 million he earned from the sale of an internet business into a new startup, X.com, which became PayPal Holdings&nbsp;about 20 years ago.</p><p><blockquote>《华尔街日报》指出，这位特斯拉首席执行官将出售互联网业务获得的2200万美元中的大部分投资于一家新初创公司X.com，该公司大约20年前成为PayPal控股公司。</blockquote></p><p></p><p> PayPal currently is among the vanguard of bitcoin revolution. PayPal&nbsp;back in November opened up its cryptocurrency platform to all U.S. customers after conducting a more narrow rollout.</p><p><blockquote>PayPal目前是比特币革命的先锋之一。PayPal早在11月就向所有美国客户开放了其加密货币平台，此前该平台进行了较窄的推广。</blockquote></p><p> Moreover, several high-profile Wall Street investors, including Stanley Druckenmiller and Paul Tudor Jones, have embraced bitcoin. Famed investor Bill Miller, founder of Miller Value Partners, in&nbsp;a letter to clients&nbsp;earlier this month&nbsp;published on the firm’s website, reaffirmed his bullish outlook on bitcoin.</p><p><blockquote>此外，包括Stanley Druckenmiller和Paul Tudor Jones在内的几位知名华尔街投资者已经接受了比特币。Miller Value Partners创始人、著名投资者Bill Miller本月早些时候在该公司网站上发表的一封致客户的信中重申了他对比特币的看涨前景。</blockquote></p><p> In other words, Tesla and Musk may be among the biggest to wade into the crypto pool, but a growing cadre of investors are starting to view the volatile digital-ledger-backed cryptos as a bona fide asset.</p><p><blockquote>换句话说，特斯拉和马斯克可能是涉足加密货币领域最大的公司之一，但越来越多的投资者开始将不稳定的数字账本支持的加密货币视为真正的资产。</blockquote></p><p> “Corporate adoption takes another leap forward with Tesla announcement,” writes Devin Ryan, analyst at JMP Securities in a Monday research note.</p><p><blockquote>JMP Securities分析师Devin Ryan在周一的研究报告中写道：“随着特斯拉的宣布，企业采用率又向前迈出了一大步。”</blockquote></p><p> The researcher, along with fellow analyst Brian McKenna, noted they “believe the building ‘network effect’ around bitcoin is moving the broader crypto asset class into the mainstream, and with many hundreds of billions of dollars of value in infrastructure supporting the asset class, we see the already substantial (and growing) vested interest in its success as bullish for the industry.”</p><p><blockquote>该研究人员和分析师同事Brian McKenna指出，他们“相信围绕比特币构建的‘网络效应’正在将更广泛的加密资产类别推向主流，并且价值数千亿美元的基础设施支持该资产类别，我们认为其成功中已经存在的大量（且不断增长）既得利益对该行业有利。”</blockquote></p><p> On Tuesday, bitcoin touched a record high around $48,000 before pulling back, as the Dow Jones Industrial Average,the S&amp;P 500&nbsp;and the Nasdaq Composite&nbsp;indexes have seen relatively tepid trade on the day.</p><p><blockquote>周二，比特币触及48,000美元左右的历史新高，随后回落，道琼斯工业平均指数、标普500和纳斯达克综合指数当天交易相对不温不火。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/why-did-tesla-buy-bitcoin-11612902220?mod=home-page\">MarketWatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"比特币ETF-Grayscale","TSLA":"特斯拉"},"source_url":"https://www.marketwatch.com/story/why-did-tesla-buy-bitcoin-11612902220?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"2110098829","content_text":"Tesla Inc. has become the latest major corporation to make an investment in bitcoin, underscoring the increasing acceptability of the digital asset.\nThe big question observers are asking is, why is the Elon Musk-run company doing this?\nMonday, electric-car maker Tesla said in a public filing that it purchased $1.5 billion of bitcoin and that it expects to begin accepting payment in the cryptocurrency for its products in the future.\nThe move by Tesla to invest in bitcoins was seen as further confirmation of the legitimacy of the nascent asset that didn’t exist until about 12 years ago.\nHowever, bitcoin is seen as a volatile asset that is prone to sharp price volatility and Monday’s announcement by Tesla was described by some corporate finance professionals as an unnecessary addition of risk to the vehicle maker’s balance sheet in the form of currency or a commodity, depending on how you classify bitcoin.\nWhile it’s not clear, at this point, why Musk & Co. have opted to expose the company to the possible risk of owning bitcoin, here are a few reasons why the revolutionary company may have aligned itself with the crypto crowd.\nDiversification\nTesla made it clear in its statement filed with its regulator the Securities and Exchange Commission that it sees bitcoin as a chance to diversify its cash and cash-equivalent holdings.\nCorporations usually hold excess cash and/or cash-equivalents, like Treasury bills or commercial paper on their books to provide operational liquidity and generate returns while limiting risks.\nTesla wrote, “we updated our investment policy to provide us with more flexibility to further diversify and maximize returns on our cash that is not required to maintain adequate operating liquidity.”\nThe move isn’t without risk, Tesla acknowledges as the price of bitcoin could slump.\n“If we hold digital assets and their values decrease relative to our purchase prices, our financial condition may be harmed,” the company acknowledges.\nBut a single bitcoin, which has soared 62% so far this year, could easily be headed for a six-digit value if bullish momentum continues to build, which would make Musk look smart.\nPublicity stunt?\n“Thankfully, Elon Musk on Monday once again ensured no one would be bored, with the unexpected announcement that Tesla will buy bitcoin and accept them as payment for vehicles,” writes Craig Erlam, senior market analyst at Oanda, in a Tuesday research note.\nThe analyst referred to the move as a “publicity stunt,” a move that everbody is talking about, but there are a number of ways to think about it.\nBrand management\nBitcoin is associated with a group of iconoclastic founders who were attempting to break the mold on payments and fiat money. That was the idea behind cryptos being written into code back in 2009 by a person or persons known as Satoshi Nakamoto.\nThose rebellious notions align somewhat with Musk’s own agenda of disruption. Tesla is making electric-powered vehicles in a world that has thus far been dominated by fossil-fuel driven cars.\nMoreover, Tesla’s direct-to-customer sales model also is viewed as trendsetting, since many companies sell their cars through unaffiliated dealerships.\nBitcoin’s image as a decentralized asset, not controlled by any one body, also fits with Tesla’s image and that of its leader Musk.\n\nThe future of $\nTesla’s $1.5 billion investment in bitcoin could also be a simple hedge against the hegemony of the U.S. dollar as the world’s reserve currency since World War Two.\nBitcoin, or something like it, represents the future of payment systems to many supporters, even if it isn’t currently an effective means of exchange due to its current volatility.\n“Yesterday’s move by Tesla to invest in bitcoin and start accepting it as payment for its own products really moved the needle,” wrote Simon Peters, cryptoasset analyst at multiasset investment platform eToro, in emailed comments.\nThe eToro analyst said that there are unconfirmed talks about technology behemoths Apple Inc. and Google-parent Alphabet Inc.,linking it to their own payment systems.\nMusk is viewed as an innovator tied to electric vehicles, batteries and space exploration via SpaceX, but one of his early ventures was in payments.\nWriting on the wall\nThe Wall Street Journal notes that, the Tesla CEO invested most of the $22 million he earned from the sale of an internet business into a new startup, X.com, which became PayPal Holdings about 20 years ago.\nPayPal currently is among the vanguard of bitcoin revolution. PayPal back in November opened up its cryptocurrency platform to all U.S. customers after conducting a more narrow rollout.\nMoreover, several high-profile Wall Street investors, including Stanley Druckenmiller and Paul Tudor Jones, have embraced bitcoin. Famed investor Bill Miller, founder of Miller Value Partners, in a letter to clients earlier this month published on the firm’s website, reaffirmed his bullish outlook on bitcoin.\nIn other words, Tesla and Musk may be among the biggest to wade into the crypto pool, but a growing cadre of investors are starting to view the volatile digital-ledger-backed cryptos as a bona fide asset.\n“Corporate adoption takes another leap forward with Tesla announcement,” writes Devin Ryan, analyst at JMP Securities in a Monday research note.\nThe researcher, along with fellow analyst Brian McKenna, noted they “believe the building ‘network effect’ around bitcoin is moving the broader crypto asset class into the mainstream, and with many hundreds of billions of dollars of value in infrastructure supporting the asset class, we see the already substantial (and growing) vested interest in its success as bullish for the industry.”\nOn Tuesday, bitcoin touched a record high around $48,000 before pulling back, as the Dow Jones Industrial Average,the S&P 500 and the Nasdaq Composite indexes have seen relatively tepid trade on the day.","news_type":1,"symbols_score_info":{"XBTmain":0.9,"BTCmain":0.9,"GBTC":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":383472650,"gmtCreate":1612889210870,"gmtModify":1703766607104,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Well said","listText":"Well said","text":"Well said","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/383472650","repostId":"1183096042","repostType":4,"isVote":1,"tweetType":1,"viewCount":648,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389605277,"gmtCreate":1612758814499,"gmtModify":1703764671813,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Amazing! Nice to know","listText":"Amazing! Nice to know","text":"Amazing! Nice to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/389605277","repostId":"1179734635","repostType":4,"repost":{"id":"1179734635","kind":"news","pubTimestamp":1612753999,"share":"https://www.laohu8.com/m/news/1179734635?lang=zh_CN&edition=full","pubTime":"2021-02-08 11:13","market":"us","language":"en","title":"5 Stocks That Can Double in a Biden Bull Market<blockquote>拜登牛市中可以翻倍的5只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1179734635","media":"The Motley Fool","summary":"The conditions are ripe for an explosive bull market to take shape under the new administration.\nThe","content":"<p>The conditions are ripe for an explosive bull market to take shape under the new administration.</p><p><blockquote>在新政府的领导下，爆炸性牛市的条件已经成熟。</blockquote></p><p> The stage is set for a potentially epic bull market to take shape with Joe Biden in the White House.</p><p><blockquote>随着乔·拜登入主白宫，一场潜在的史诗般的牛市即将形成。</blockquote></p><p> Volatility remains high and the U.S. economy is still finding its footing after one of the steepest recessions in decades. Still, historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and multiple rounds of fiscal stimulus from Washington could light a fire under equities. With access to cheap capital, growth stocks with clear-cut competitive advantages should face few hurdles.</p><p><blockquote>波动性仍然很高，美国经济在经历了几十年来最严重的衰退之一后仍在站稳脚跟。尽管如此，处于历史低位的贷款利率、美联储持续的量化宽松措施以及华盛顿的多轮财政刺激措施可能会点燃股市的火焰。由于能够获得廉价资本，具有明显竞争优势的成长型股票应该不会面临什么障碍。</blockquote></p><p> If you're looking to grow your wealth by taking advantage of what could be an explosive Biden bull market, the following five stocks could be just what you need to double your money.</p><p><blockquote>如果您想利用拜登爆炸性牛市来增加财富，那么以下五只股票可能正是您让资金翻倍所需的。</blockquote></p><p> <b>Fastly</b></p><p><blockquote><b>快速地</b></blockquote></p><p> Let's begin with edge cloud services provider&nbsp;<b>Fastly</b>(NYSE:FSLY). This company is responsible for securely and expeditiously delivering content to end users. It's benefited nicely from businesses shifting their traffic online, a long-term trend that the pandemic accelerated.&nbsp;Fastly has proven to be a go-to edge cloud provider, and willcontinue to be as online traffic surgesin the years to come.</p><p><blockquote>让我们从边缘云服务提供商开始<b>快速地</b>（纽约证券交易所代码：FSLY）。该公司负责安全、快速地向最终用户交付内容。它很好地受益于企业将流量转移到网上，这是疫情加速的一个长期趋势。事实证明，Fastly是首选的边缘云提供商，并将在未来几年随着在线流量的激增而继续如此。</blockquote></p><p> Fastly growth from existing clients is extremely impressive. Even after TikTok parent ByteDance pulled most of its traffic off Fastly's network in the third quarter (TikTok was Fastly's biggest customer by revenue in the first-half of 2020, and was embroiled in a spat with the Trump administration during Q3), Fastly's sales jumped 42%. The bulk of this growth came from existing clients, with the company reporting a&nbsp;dollar-based net expansion rate of 147%.</p><p><blockquote>现有客户的快速增长令人印象深刻。即使在TikTok母公司字节跳动在第三季度从Fastly的网络中撤出大部分流量（按收入计算，TikTok是Fastly 2020年上半年最大的客户，并在第三季度卷入了与特朗普政府的争执）之后，Fastly的销售额仍增长了42%。这一增长大部分来自现有客户，该公司报告以美元计算的净增长率为147%。</blockquote></p><p> Having existing clients spend more is Fastly's ticket to recurring profits, and should play a key role in doubling its share price.</p><p><blockquote>让现有客户增加支出是Fastly获得经常性利润的门票，并且应该在其股价翻倍方面发挥关键作用。</blockquote></p><p> <b>Teladoc Health</b></p><p><blockquote><b>Teladoc健康</b></blockquote></p><p> Precision medicine should be a slam-dunk growth trend in a Biden bull market, which is why&nbsp;<b>Teladoc Health</b>(NYSE:TDOC)is such a smart stock to buy.</p><p><blockquote>在拜登牛市中，精准医疗应该是一个强劲的增长趋势，这就是为什么<b>Teladoc健康</b>（纽约证券交易所股票代码：TDOC）是一只值得购买的明智股票。</blockquote></p><p> As the name suggests, Teladoc is a leading telehealth services company. Like Fastly, it was able totake advantageof the coronavirus disease 2019 (COVID-19) pandemic. Between April 2020 and September 2020, virtual appointments more than tripled. Telehealth will remain an important part of the U.S. healthcare system even after the pandemic ends. It's more convenient for patients and physicians, and virtual visits are billed at a lower cost than office visits for insurers.</p><p><blockquote>顾名思义，Teladoc是一家领先的远程医疗服务公司。与Fastly一样，它能够利用冠状病毒疾病2019（COVID-19）大流行。2020年4月至2020年9月期间，虚拟预约增加了两倍多。即使在疫情结束后，远程医疗仍将是美国医疗保健系统的重要组成部分。这对病人和医生来说更方便，而且对保险公司来说，虚拟就诊的费用比办公室就诊更低。</blockquote></p><p> Beyond telemedicine, Teladoc also acquired applied health signals company Livongo Health in early November. Livongo has already turned the corner to profitability, despite only securing a little over 1% of the U.S. diabetes market. Livongo offers tips and nudges to help chronically ill patients lead healthier lives. It's looking to expand this service to patients with hypertension and weight management concerns in the months and years to come. In other words, Livongomakes the fast-growing Teladoc that much better.</p><p><blockquote>除了远程医疗之外，Teladoc还在11月初收购了应用健康信号公司Livongo Health。尽管Livongo仅占据美国糖尿病市场1%多一点的份额，但它已经扭亏为盈。Livongo提供提示和提示，帮助慢性病患者过上更健康的生活。它希望在未来几个月和几年内将这项服务扩展到有高血压和体重管理问题的患者。换句话说，Livongo让快速增长的Teladoc变得更好。</blockquote></p><p> <b>Cresco Labs</b></p><p><blockquote><b>Cresco实验室</b></blockquote></p><p> The marijuana industry is finally beginning to mature, and ahandful of winners are emerging. Multistate operator&nbsp;<b>Cresco Labs</b>(OTC:CRLBF)is one such name to get onto your buy list.</p><p><blockquote>大麻产业终于开始成熟，少数赢家正在出现。多状态算子<b>Cresco实验室</b>（场外交易代码：CRLBF）就是这样一个值得列入您购买清单的名字。</blockquote></p><p> Cresco and most other U.S.marijuana stocksdon't need any action from the Biden administration to thrive. Having states set their own cannabis guidelines has been working fine for Cresco. In fact, the company has two key catalysts driving its growth that could push total sales above $1 billion by as early as 2022.</p><p><blockquote>Cresco和大多数其他美国大麻股票不需要拜登政府采取任何行动就能蓬勃发展。让各州制定自己的大麻指导方针对Cresco来说效果很好。事实上，该公司有两个推动其增长的关键催化剂，最早可能在2022年将总销售额推至10亿美元以上。</blockquote></p><p> First, Cresco has its retail operations: 20 open dispensaries, 10 of which are in Illinois. The Land of Lincoln is a limited license state that registered $1 billion in cannabis sales in its first year of recreational legalization.</p><p><blockquote>首先，Cresco拥有零售业务：20家开放药房，其中10家位于伊利诺伊州。林肯之地是一个有限许可的州，在娱乐合法化的第一年，大麻销售额就达到了10亿美元。</blockquote></p><p> Second, Cresco Labs is a wholesale marijuana kingpin in California, the most lucrative weed market in the world by annual sales. Purchasing Origin House in January 2020 gave Cresco access to the company's cannabis distribution license. Nowadays, it's able to place cannabis products into more than 575 dispensaries throughout the Golden State.</p><p><blockquote>其次，Cresco Labs是加利福尼亚州的大麻批发巨头，按年销售额计算，加利福尼亚州是世界上最赚钱的大麻市场。2020年1月收购Origin House使Cresco获得了该公司的大麻分销许可证。如今，它能够将大麻产品放入整个金州超过575家药房。</blockquote></p><p> <b>Ping Identity</b></p><p><blockquote><b>Ping标识</b></blockquote></p><p> Investors should also expect cybersecurity stocks like&nbsp;<b>Ping Identity</b>(NYSE:PING)to thrive in a Biden bull market.</p><p><blockquote>投资者还应该期待网络安全股票，例如<b>Ping标识</b>（纽约证券交易所股票代码：PING）在拜登牛市中蓬勃发展。</blockquote></p><p> The beauty of businesses moving online and into the cloud is that it creates a growing demand for data protection.Cybersecurity is no longer optional. No matter the size of a business or the state of the local or global economy, hackers and robots don't take time off.</p><p><blockquote>企业转移到网上和云端的美妙之处在于，它创造了不断增长的数据保护需求。网络安全不再是可有可无的。无论企业规模如何，也无论当地或全球经济状况如何，黑客和机器人都不会请假。</blockquote></p><p> One of the many companies at the heart of data protection is Ping Identity. Ping relies on artificial intelligence to help its identity verification solutions grow smarter over time. The more clients Ping lands, the more effective its identity solutions are at identifying unique threats to enterprise data.</p><p><blockquote>Ping Identity是数据保护核心的众多公司之一。随着时间的推移，Ping依靠人工智能来帮助其身份验证解决方案变得更加智能。Ping登陆的客户端越多，其身份解决方案在识别企业数据的独特威胁方面就越有效。</blockquote></p><p></p><p> What's more, Ping doesn't trade at 20 or 30 times sales like most cybersecurity stocks. Ping can be scooped up for about 9 times Wall Street's consensus 2021 sales, yet looks to be on track for sustainable low double-digit growth moving forward. That's&nbsp;growth and value wrapped up in a single stock.</p><p><blockquote>更重要的是，Ping的交易价格不像大多数网络安全股票那样是销售额的20或30倍。Ping的销售额约为华尔街2021年共识销售额的9倍，但未来有望实现可持续的低两位数增长。这就是一只股票的增长和价值。</blockquote></p><p> <b>Redfin</b></p><p><blockquote><b>Redfin</b></blockquote></p><p> A Biden bull market should be kind to innovative real estate companies, too. That's why<b>Redfin</b>(NASDAQ:RDFN)has a really good chance of doubling with Biden in the White House.</p><p><blockquote>拜登牛市也应该善待创新型房地产公司。这就是为什么<b>Redfin</b>（纳斯达克：RDFN）很有可能与拜登一起入主白宫。</blockquote></p><p> On one hand, macroeconomic factors are playing right into Redfin's hands. The Fed has every intention of keeping its federal funds target rate at or near record lows through 2023. Plus, as noted, the nation's central bank is buying government debt each month, which could further push Treasury rates down. This all points to historically low mortgage rates and a red-hot market for housing.</p><p><blockquote>一方面，宏观经济因素正对Redfin有利。美联储完全打算在2023年之前将其联邦基金目标利率保持在或接近历史低点。此外，如前所述，该国央行每月都会购买政府债务，这可能会进一步压低国债利率。这一切都表明抵押贷款利率处于历史低位，房地产市场火热。</blockquote></p><p> On the other hand, it's all about what Redfin brings to the table to differentiate itself from the competition. For example, Redfin'slisting rates of 1% to 1.5%are up to 2 percentage points lower than traditional commission fees.</p><p><blockquote>另一方面，这完全取决于Redfin带来了什么来使自己在竞争中脱颖而出。例如，Redfin 1%至1.5%的上市费率比传统佣金低2个百分点。</blockquote></p><p> Additionally, this is a company thatoffers a number of high-margin ease-of-use servicesthat simplify the buying process. This includes everything from Redfin simply acquiring homes from sellers for a flat fee (these homes are held as inventory and sold later), to homeowners paying Redfin to handle title, appraisal, and home inspection paperwork. It's a growth stock with serious upside still to come.</p><p><blockquote>此外，这家公司还提供许多高利润的易用服务，简化了购买流程。这包括从Redfin简单地以固定费用从卖家那里收购房屋（这些房屋作为库存持有，稍后出售），到房主向Redfin支付处理产权、评估和房屋检查文书工作的费用。这是一只成长型股票，仍有很大的上涨空间。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks That Can Double in a Biden Bull Market<blockquote>拜登牛市中可以翻倍的5只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks That Can Double in a Biden Bull Market<blockquote>拜登牛市中可以翻倍的5只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-02-08 11:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The conditions are ripe for an explosive bull market to take shape under the new administration.</p><p><blockquote>在新政府的领导下，爆炸性牛市的条件已经成熟。</blockquote></p><p> The stage is set for a potentially epic bull market to take shape with Joe Biden in the White House.</p><p><blockquote>随着乔·拜登入主白宫，一场潜在的史诗般的牛市即将形成。</blockquote></p><p> Volatility remains high and the U.S. economy is still finding its footing after one of the steepest recessions in decades. Still, historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and multiple rounds of fiscal stimulus from Washington could light a fire under equities. With access to cheap capital, growth stocks with clear-cut competitive advantages should face few hurdles.</p><p><blockquote>波动性仍然很高，美国经济在经历了几十年来最严重的衰退之一后仍在站稳脚跟。尽管如此，处于历史低位的贷款利率、美联储持续的量化宽松措施以及华盛顿的多轮财政刺激措施可能会点燃股市的火焰。由于能够获得廉价资本，具有明显竞争优势的成长型股票应该不会面临什么障碍。</blockquote></p><p> If you're looking to grow your wealth by taking advantage of what could be an explosive Biden bull market, the following five stocks could be just what you need to double your money.</p><p><blockquote>如果您想利用拜登爆炸性牛市来增加财富，那么以下五只股票可能正是您让资金翻倍所需的。</blockquote></p><p> <b>Fastly</b></p><p><blockquote><b>快速地</b></blockquote></p><p> Let's begin with edge cloud services provider&nbsp;<b>Fastly</b>(NYSE:FSLY). This company is responsible for securely and expeditiously delivering content to end users. It's benefited nicely from businesses shifting their traffic online, a long-term trend that the pandemic accelerated.&nbsp;Fastly has proven to be a go-to edge cloud provider, and willcontinue to be as online traffic surgesin the years to come.</p><p><blockquote>让我们从边缘云服务提供商开始<b>快速地</b>（纽约证券交易所代码：FSLY）。该公司负责安全、快速地向最终用户交付内容。它很好地受益于企业将流量转移到网上，这是疫情加速的一个长期趋势。事实证明，Fastly是首选的边缘云提供商，并将在未来几年随着在线流量的激增而继续如此。</blockquote></p><p> Fastly growth from existing clients is extremely impressive. Even after TikTok parent ByteDance pulled most of its traffic off Fastly's network in the third quarter (TikTok was Fastly's biggest customer by revenue in the first-half of 2020, and was embroiled in a spat with the Trump administration during Q3), Fastly's sales jumped 42%. The bulk of this growth came from existing clients, with the company reporting a&nbsp;dollar-based net expansion rate of 147%.</p><p><blockquote>现有客户的快速增长令人印象深刻。即使在TikTok母公司字节跳动在第三季度从Fastly的网络中撤出大部分流量（按收入计算，TikTok是Fastly 2020年上半年最大的客户，并在第三季度卷入了与特朗普政府的争执）之后，Fastly的销售额仍增长了42%。这一增长大部分来自现有客户，该公司报告以美元计算的净增长率为147%。</blockquote></p><p> Having existing clients spend more is Fastly's ticket to recurring profits, and should play a key role in doubling its share price.</p><p><blockquote>让现有客户增加支出是Fastly获得经常性利润的门票，并且应该在其股价翻倍方面发挥关键作用。</blockquote></p><p> <b>Teladoc Health</b></p><p><blockquote><b>Teladoc健康</b></blockquote></p><p> Precision medicine should be a slam-dunk growth trend in a Biden bull market, which is why&nbsp;<b>Teladoc Health</b>(NYSE:TDOC)is such a smart stock to buy.</p><p><blockquote>在拜登牛市中，精准医疗应该是一个强劲的增长趋势，这就是为什么<b>Teladoc健康</b>（纽约证券交易所股票代码：TDOC）是一只值得购买的明智股票。</blockquote></p><p> As the name suggests, Teladoc is a leading telehealth services company. Like Fastly, it was able totake advantageof the coronavirus disease 2019 (COVID-19) pandemic. Between April 2020 and September 2020, virtual appointments more than tripled. Telehealth will remain an important part of the U.S. healthcare system even after the pandemic ends. It's more convenient for patients and physicians, and virtual visits are billed at a lower cost than office visits for insurers.</p><p><blockquote>顾名思义，Teladoc是一家领先的远程医疗服务公司。与Fastly一样，它能够利用冠状病毒疾病2019（COVID-19）大流行。2020年4月至2020年9月期间，虚拟预约增加了两倍多。即使在疫情结束后，远程医疗仍将是美国医疗保健系统的重要组成部分。这对病人和医生来说更方便，而且对保险公司来说，虚拟就诊的费用比办公室就诊更低。</blockquote></p><p> Beyond telemedicine, Teladoc also acquired applied health signals company Livongo Health in early November. Livongo has already turned the corner to profitability, despite only securing a little over 1% of the U.S. diabetes market. Livongo offers tips and nudges to help chronically ill patients lead healthier lives. It's looking to expand this service to patients with hypertension and weight management concerns in the months and years to come. In other words, Livongomakes the fast-growing Teladoc that much better.</p><p><blockquote>除了远程医疗之外，Teladoc还在11月初收购了应用健康信号公司Livongo Health。尽管Livongo仅占据美国糖尿病市场1%多一点的份额，但它已经扭亏为盈。Livongo提供提示和提示，帮助慢性病患者过上更健康的生活。它希望在未来几个月和几年内将这项服务扩展到有高血压和体重管理问题的患者。换句话说，Livongo让快速增长的Teladoc变得更好。</blockquote></p><p> <b>Cresco Labs</b></p><p><blockquote><b>Cresco实验室</b></blockquote></p><p> The marijuana industry is finally beginning to mature, and ahandful of winners are emerging. Multistate operator&nbsp;<b>Cresco Labs</b>(OTC:CRLBF)is one such name to get onto your buy list.</p><p><blockquote>大麻产业终于开始成熟，少数赢家正在出现。多状态算子<b>Cresco实验室</b>（场外交易代码：CRLBF）就是这样一个值得列入您购买清单的名字。</blockquote></p><p> Cresco and most other U.S.marijuana stocksdon't need any action from the Biden administration to thrive. Having states set their own cannabis guidelines has been working fine for Cresco. In fact, the company has two key catalysts driving its growth that could push total sales above $1 billion by as early as 2022.</p><p><blockquote>Cresco和大多数其他美国大麻股票不需要拜登政府采取任何行动就能蓬勃发展。让各州制定自己的大麻指导方针对Cresco来说效果很好。事实上，该公司有两个推动其增长的关键催化剂，最早可能在2022年将总销售额推至10亿美元以上。</blockquote></p><p> First, Cresco has its retail operations: 20 open dispensaries, 10 of which are in Illinois. The Land of Lincoln is a limited license state that registered $1 billion in cannabis sales in its first year of recreational legalization.</p><p><blockquote>首先，Cresco拥有零售业务：20家开放药房，其中10家位于伊利诺伊州。林肯之地是一个有限许可的州，在娱乐合法化的第一年，大麻销售额就达到了10亿美元。</blockquote></p><p> Second, Cresco Labs is a wholesale marijuana kingpin in California, the most lucrative weed market in the world by annual sales. Purchasing Origin House in January 2020 gave Cresco access to the company's cannabis distribution license. Nowadays, it's able to place cannabis products into more than 575 dispensaries throughout the Golden State.</p><p><blockquote>其次，Cresco Labs是加利福尼亚州的大麻批发巨头，按年销售额计算，加利福尼亚州是世界上最赚钱的大麻市场。2020年1月收购Origin House使Cresco获得了该公司的大麻分销许可证。如今，它能够将大麻产品放入整个金州超过575家药房。</blockquote></p><p> <b>Ping Identity</b></p><p><blockquote><b>Ping标识</b></blockquote></p><p> Investors should also expect cybersecurity stocks like&nbsp;<b>Ping Identity</b>(NYSE:PING)to thrive in a Biden bull market.</p><p><blockquote>投资者还应该期待网络安全股票，例如<b>Ping标识</b>（纽约证券交易所股票代码：PING）在拜登牛市中蓬勃发展。</blockquote></p><p> The beauty of businesses moving online and into the cloud is that it creates a growing demand for data protection.Cybersecurity is no longer optional. No matter the size of a business or the state of the local or global economy, hackers and robots don't take time off.</p><p><blockquote>企业转移到网上和云端的美妙之处在于，它创造了不断增长的数据保护需求。网络安全不再是可有可无的。无论企业规模如何，也无论当地或全球经济状况如何，黑客和机器人都不会请假。</blockquote></p><p> One of the many companies at the heart of data protection is Ping Identity. Ping relies on artificial intelligence to help its identity verification solutions grow smarter over time. The more clients Ping lands, the more effective its identity solutions are at identifying unique threats to enterprise data.</p><p><blockquote>Ping Identity是数据保护核心的众多公司之一。随着时间的推移，Ping依靠人工智能来帮助其身份验证解决方案变得更加智能。Ping登陆的客户端越多，其身份解决方案在识别企业数据的独特威胁方面就越有效。</blockquote></p><p></p><p> What's more, Ping doesn't trade at 20 or 30 times sales like most cybersecurity stocks. Ping can be scooped up for about 9 times Wall Street's consensus 2021 sales, yet looks to be on track for sustainable low double-digit growth moving forward. That's&nbsp;growth and value wrapped up in a single stock.</p><p><blockquote>更重要的是，Ping的交易价格不像大多数网络安全股票那样是销售额的20或30倍。Ping的销售额约为华尔街2021年共识销售额的9倍，但未来有望实现可持续的低两位数增长。这就是一只股票的增长和价值。</blockquote></p><p> <b>Redfin</b></p><p><blockquote><b>Redfin</b></blockquote></p><p> A Biden bull market should be kind to innovative real estate companies, too. That's why<b>Redfin</b>(NASDAQ:RDFN)has a really good chance of doubling with Biden in the White House.</p><p><blockquote>拜登牛市也应该善待创新型房地产公司。这就是为什么<b>Redfin</b>（纳斯达克：RDFN）很有可能与拜登一起入主白宫。</blockquote></p><p> On one hand, macroeconomic factors are playing right into Redfin's hands. The Fed has every intention of keeping its federal funds target rate at or near record lows through 2023. Plus, as noted, the nation's central bank is buying government debt each month, which could further push Treasury rates down. This all points to historically low mortgage rates and a red-hot market for housing.</p><p><blockquote>一方面，宏观经济因素正对Redfin有利。美联储完全打算在2023年之前将其联邦基金目标利率保持在或接近历史低点。此外，如前所述，该国央行每月都会购买政府债务，这可能会进一步压低国债利率。这一切都表明抵押贷款利率处于历史低位，房地产市场火热。</blockquote></p><p> On the other hand, it's all about what Redfin brings to the table to differentiate itself from the competition. For example, Redfin'slisting rates of 1% to 1.5%are up to 2 percentage points lower than traditional commission fees.</p><p><blockquote>另一方面，这完全取决于Redfin带来了什么来使自己在竞争中脱颖而出。例如，Redfin 1%至1.5%的上市费率比传统佣金低2个百分点。</blockquote></p><p> Additionally, this is a company thatoffers a number of high-margin ease-of-use servicesthat simplify the buying process. This includes everything from Redfin simply acquiring homes from sellers for a flat fee (these homes are held as inventory and sold later), to homeowners paying Redfin to handle title, appraisal, and home inspection paperwork. It's a growth stock with serious upside still to come.</p><p><blockquote>此外，这家公司还提供许多高利润的易用服务，简化了购买流程。这包括从Redfin简单地以固定费用从卖家那里收购房屋（这些房屋作为库存持有，稍后出售），到房主向Redfin支付处理产权、评估和房屋检查文书工作的费用。这是一只成长型股票，仍有很大的上涨空间。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/02/07/5-stocks-that-can-double-in-a-biden-bull-market/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","CRLBF":"Cresco Labs Inc.","RDFN":"Redfin Corp","FSLY":"Fastly, Inc.","PING":"Ping Identity Holding"},"source_url":"https://www.fool.com/investing/2021/02/07/5-stocks-that-can-double-in-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179734635","content_text":"The conditions are ripe for an explosive bull market to take shape under the new administration.\nThe stage is set for a potentially epic bull market to take shape with Joe Biden in the White House.\nVolatility remains high and the U.S. economy is still finding its footing after one of the steepest recessions in decades. Still, historically low lending rates, ongoing quantitative easing measures from the Federal Reserve, and multiple rounds of fiscal stimulus from Washington could light a fire under equities. With access to cheap capital, growth stocks with clear-cut competitive advantages should face few hurdles.\nIf you're looking to grow your wealth by taking advantage of what could be an explosive Biden bull market, the following five stocks could be just what you need to double your money.\nFastly\nLet's begin with edge cloud services provider Fastly(NYSE:FSLY). This company is responsible for securely and expeditiously delivering content to end users. It's benefited nicely from businesses shifting their traffic online, a long-term trend that the pandemic accelerated. Fastly has proven to be a go-to edge cloud provider, and willcontinue to be as online traffic surgesin the years to come.\nFastly growth from existing clients is extremely impressive. Even after TikTok parent ByteDance pulled most of its traffic off Fastly's network in the third quarter (TikTok was Fastly's biggest customer by revenue in the first-half of 2020, and was embroiled in a spat with the Trump administration during Q3), Fastly's sales jumped 42%. The bulk of this growth came from existing clients, with the company reporting a dollar-based net expansion rate of 147%.\nHaving existing clients spend more is Fastly's ticket to recurring profits, and should play a key role in doubling its share price.\nTeladoc Health\nPrecision medicine should be a slam-dunk growth trend in a Biden bull market, which is why Teladoc Health(NYSE:TDOC)is such a smart stock to buy.\nAs the name suggests, Teladoc is a leading telehealth services company. Like Fastly, it was able totake advantageof the coronavirus disease 2019 (COVID-19) pandemic. Between April 2020 and September 2020, virtual appointments more than tripled. Telehealth will remain an important part of the U.S. healthcare system even after the pandemic ends. It's more convenient for patients and physicians, and virtual visits are billed at a lower cost than office visits for insurers.\nBeyond telemedicine, Teladoc also acquired applied health signals company Livongo Health in early November. Livongo has already turned the corner to profitability, despite only securing a little over 1% of the U.S. diabetes market. Livongo offers tips and nudges to help chronically ill patients lead healthier lives. It's looking to expand this service to patients with hypertension and weight management concerns in the months and years to come. In other words, Livongomakes the fast-growing Teladoc that much better.\nCresco Labs\nThe marijuana industry is finally beginning to mature, and ahandful of winners are emerging. Multistate operator Cresco Labs(OTC:CRLBF)is one such name to get onto your buy list.\nCresco and most other U.S.marijuana stocksdon't need any action from the Biden administration to thrive. Having states set their own cannabis guidelines has been working fine for Cresco. In fact, the company has two key catalysts driving its growth that could push total sales above $1 billion by as early as 2022.\nFirst, Cresco has its retail operations: 20 open dispensaries, 10 of which are in Illinois. The Land of Lincoln is a limited license state that registered $1 billion in cannabis sales in its first year of recreational legalization.\nSecond, Cresco Labs is a wholesale marijuana kingpin in California, the most lucrative weed market in the world by annual sales. Purchasing Origin House in January 2020 gave Cresco access to the company's cannabis distribution license. Nowadays, it's able to place cannabis products into more than 575 dispensaries throughout the Golden State.\nPing Identity\nInvestors should also expect cybersecurity stocks like Ping Identity(NYSE:PING)to thrive in a Biden bull market.\nThe beauty of businesses moving online and into the cloud is that it creates a growing demand for data protection.Cybersecurity is no longer optional. No matter the size of a business or the state of the local or global economy, hackers and robots don't take time off.\nOne of the many companies at the heart of data protection is Ping Identity. Ping relies on artificial intelligence to help its identity verification solutions grow smarter over time. The more clients Ping lands, the more effective its identity solutions are at identifying unique threats to enterprise data.\nWhat's more, Ping doesn't trade at 20 or 30 times sales like most cybersecurity stocks. Ping can be scooped up for about 9 times Wall Street's consensus 2021 sales, yet looks to be on track for sustainable low double-digit growth moving forward. That's growth and value wrapped up in a single stock.\nRedfin\nA Biden bull market should be kind to innovative real estate companies, too. That's whyRedfin(NASDAQ:RDFN)has a really good chance of doubling with Biden in the White House.\nOn one hand, macroeconomic factors are playing right into Redfin's hands. The Fed has every intention of keeping its federal funds target rate at or near record lows through 2023. Plus, as noted, the nation's central bank is buying government debt each month, which could further push Treasury rates down. This all points to historically low mortgage rates and a red-hot market for housing.\nOn the other hand, it's all about what Redfin brings to the table to differentiate itself from the competition. For example, Redfin'slisting rates of 1% to 1.5%are up to 2 percentage points lower than traditional commission fees.\nAdditionally, this is a company thatoffers a number of high-margin ease-of-use servicesthat simplify the buying process. This includes everything from Redfin simply acquiring homes from sellers for a flat fee (these homes are held as inventory and sold later), to homeowners paying Redfin to handle title, appraisal, and home inspection paperwork. It's a growth stock with serious upside still to come.","news_type":1,"symbols_score_info":{"TDOC":0.9,"CRLBF":0.9,"PING":0.9,"RDFN":0.9,"FSLY":0.9}},"isVote":1,"tweetType":1,"viewCount":588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":389009470,"gmtCreate":1612608990590,"gmtModify":1703763975662,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/389009470","repostId":"2109727286","repostType":4,"isVote":1,"tweetType":1,"viewCount":605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314141902,"gmtCreate":1612324160006,"gmtModify":1703760364950,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314141902","repostId":"1172237562","repostType":2,"repost":{"id":"1172237562","kind":"news","pubTimestamp":1612320389,"share":"https://www.laohu8.com/m/news/1172237562?lang=zh_CN&edition=full","pubTime":"2021-02-03 10:46","market":"us","language":"en","title":"Short-sellers were pulling back even before Reddit’s GameStop squeeze<blockquote>甚至在Reddit的游戏驿站挤压之前，卖空者就已经撤退了</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172237562","media":"marketwatch","summary":"Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but shor","content":"<p>Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but short-selling may be helping to keep the bull market alive.</p><p><blockquote>GameStopGME、-60.00%和其他目标股票的卖空者最近受到了打击，但卖空可能有助于保持牛市的活力。</blockquote></p><p> Short-selling, according to academic research, has strong predictive power for the U.S. stock market’s subsequent 12-month return. Right now, short interest is unusually low, says Matthew Ringgenberg, a finance professor at the University of Utah.</p><p><blockquote>做空，根据学术研究，对美国股市随后12个月的回报有很强的预测力。犹他大学金融学教授马修·林根伯格表示，目前空头兴趣异常低。</blockquote></p><p> Ringgenberg is a leading expert on the behavior of short sellers. In an interview, he observed: “Even before the recent short squeezes, short interest in December and January was approaching historically low levels. In fact, with the exception of December 2018, this is the lowest short interest has been since before the 2008 crisis.” The data to which he is referring are plotted in the chart below.</p><p><blockquote>林根伯格是卖空者行为方面的领先专家。他在接受采访时观察到：“即使在最近的空头挤压之前，12月和1月的空头兴趣也接近历史低位。事实上，除了2018年12月，这是自2008年危机前以来空头兴趣的最低水平。”他所指的数据绘制在下图中。</blockquote></p><p> Be wary of contrarian investors who interpret low short interest as bearish. Ringgenberg says the contrarians are wrong; his research has found that the short sellers on balance are more right than not.</p><p><blockquote>警惕将空头兴趣低解读为看跌的逆向投资者。林根伯格表示，逆向投资者是错误的；他的研究发现，总的来说，卖空者是正确的。</blockquote></p><p> Note carefully that the chart focuses on the raw short interest ratio. As I have reported in prior columns about Ringgenberg’s research, he has found that the predictive power of the ratio can be improved by calculating where it stands relative to its underlying trend. This adjusted ratio, he adds, is even more bullish than the raw unadjusted ratio.</p><p><blockquote>请仔细注意，该图表重点关注原始空头利率。正如我在之前关于林根伯格研究的专栏中报道的那样，他发现可以通过计算该比率相对于其潜在趋势的位置来提高该比率的预测能力。他补充说，这一调整后的比率甚至比未经调整的原始比率更加乐观。</blockquote></p><p> Note also that the investment horizon for which this adjusted ratio has shown explanatory power is 12 months. So even if the current prediction is spot-on, it tells us nothing about the path the market takes along the way. It could be, for example, that the S&amp;P 500SPX,+1.39%is higher in 12 months while suffering a steep decline along the way. That’s what happened over the past year.</p><p><blockquote>另请注意，该调整后比率显示出解释力的投资期限为12个月。因此，即使目前的预测是准确的，它也没有告诉我们任何关于市场前进道路的信息。例如，标准普尔500SPX指数可能会在12个月内上涨+1.39%，同时在此过程中大幅下跌。这就是过去一年发生的事情。</blockquote></p><p> <b>One big caveat</b></p><p><blockquote><b>一个大警告</b></blockquote></p><p> Ringgenberg says that on rare occasions, short sellers are particularly bearish but nevertheless choose not to aggressively sell short. This occurs most typically when investor sentiment is exuberant, the market is volatile, and when certain stocks are trading without any discernible relationship to their underlying fundamentals. During such times, he said, the already-high risks that short sellers face grow to intolerable levels—and many of them retreat to the sidelines.</p><p><blockquote>林根伯格表示，在极少数情况下，卖空者特别看跌，但仍然选择不大幅卖空。当投资者情绪旺盛、市场波动以及某些股票的交易与其基本面没有任何明显关系时，这种情况最常见。他说，在这种时候，卖空者面临的本已很高的风险会增长到无法忍受的水平，他们中的许多人会退缩到观望状态。</blockquote></p><p> I mentioned this phenomenon, referred to as the “limits to arbitrage,” in acolumn last week about the GameStop saga. Perhaps the most prominent historical example of it came at the end of the internet bubble when a number of dot-com companies with no assets, revenue or business plan were propelled to sky-high valuations. The short interest ratio actually declined from 1998 through 2000 despite ever-rising valuations.</p><p><blockquote>我在上周关于游戏驿站传奇的专栏中提到了这种被称为“套利极限”的现象。也许最突出的历史例子出现在互联网泡沫结束时，当时许多没有资产、收入或商业计划的互联网公司被推到了天价估值。尽管估值不断上升，但从1998年到2000年，空头利率实际上有所下降。</blockquote></p><p> There are some who currently believe we’re in a bubble similar to the late 1990s. If they’re right, then we should not make too much of short sellers’ lack of aggressiveness. Absent that possibility, the message of the short-sale ratio is bullish for the next 12 months.</p><p><blockquote>目前有些人认为我们正处于类似于20世纪90年代末的泡沫之中。如果他们是对的，那么我们不应该过分强调卖空者缺乏侵略性。如果没有这种可能性，卖空比率的信息在未来12个月是看涨的。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Short-sellers were pulling back even before Reddit’s GameStop squeeze<blockquote>甚至在Reddit的游戏驿站挤压之前，卖空者就已经撤退了</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShort-sellers were pulling back even before Reddit’s GameStop squeeze<blockquote>甚至在Reddit的游戏驿站挤压之前，卖空者就已经撤退了</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">marketwatch</strong><span class=\"h-time small\">2021-02-03 10:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but short-selling may be helping to keep the bull market alive.</p><p><blockquote>GameStopGME、-60.00%和其他目标股票的卖空者最近受到了打击，但卖空可能有助于保持牛市的活力。</blockquote></p><p> Short-selling, according to academic research, has strong predictive power for the U.S. stock market’s subsequent 12-month return. Right now, short interest is unusually low, says Matthew Ringgenberg, a finance professor at the University of Utah.</p><p><blockquote>做空，根据学术研究，对美国股市随后12个月的回报有很强的预测力。犹他大学金融学教授马修·林根伯格表示，目前空头兴趣异常低。</blockquote></p><p> Ringgenberg is a leading expert on the behavior of short sellers. In an interview, he observed: “Even before the recent short squeezes, short interest in December and January was approaching historically low levels. In fact, with the exception of December 2018, this is the lowest short interest has been since before the 2008 crisis.” The data to which he is referring are plotted in the chart below.</p><p><blockquote>林根伯格是卖空者行为方面的领先专家。他在接受采访时观察到：“即使在最近的空头挤压之前，12月和1月的空头兴趣也接近历史低位。事实上，除了2018年12月，这是自2008年危机前以来空头兴趣的最低水平。”他所指的数据绘制在下图中。</blockquote></p><p> Be wary of contrarian investors who interpret low short interest as bearish. Ringgenberg says the contrarians are wrong; his research has found that the short sellers on balance are more right than not.</p><p><blockquote>警惕将空头兴趣低解读为看跌的逆向投资者。林根伯格表示，逆向投资者是错误的；他的研究发现，总的来说，卖空者是正确的。</blockquote></p><p> Note carefully that the chart focuses on the raw short interest ratio. As I have reported in prior columns about Ringgenberg’s research, he has found that the predictive power of the ratio can be improved by calculating where it stands relative to its underlying trend. This adjusted ratio, he adds, is even more bullish than the raw unadjusted ratio.</p><p><blockquote>请仔细注意，该图表重点关注原始空头利率。正如我在之前关于林根伯格研究的专栏中报道的那样，他发现可以通过计算该比率相对于其潜在趋势的位置来提高该比率的预测能力。他补充说，这一调整后的比率甚至比未经调整的原始比率更加乐观。</blockquote></p><p> Note also that the investment horizon for which this adjusted ratio has shown explanatory power is 12 months. So even if the current prediction is spot-on, it tells us nothing about the path the market takes along the way. It could be, for example, that the S&amp;P 500SPX,+1.39%is higher in 12 months while suffering a steep decline along the way. That’s what happened over the past year.</p><p><blockquote>另请注意，该调整后比率显示出解释力的投资期限为12个月。因此，即使目前的预测是准确的，它也没有告诉我们任何关于市场前进道路的信息。例如，标准普尔500SPX指数可能会在12个月内上涨+1.39%，同时在此过程中大幅下跌。这就是过去一年发生的事情。</blockquote></p><p> <b>One big caveat</b></p><p><blockquote><b>一个大警告</b></blockquote></p><p> Ringgenberg says that on rare occasions, short sellers are particularly bearish but nevertheless choose not to aggressively sell short. This occurs most typically when investor sentiment is exuberant, the market is volatile, and when certain stocks are trading without any discernible relationship to their underlying fundamentals. During such times, he said, the already-high risks that short sellers face grow to intolerable levels—and many of them retreat to the sidelines.</p><p><blockquote>林根伯格表示，在极少数情况下，卖空者特别看跌，但仍然选择不大幅卖空。当投资者情绪旺盛、市场波动以及某些股票的交易与其基本面没有任何明显关系时，这种情况最常见。他说，在这种时候，卖空者面临的本已很高的风险会增长到无法忍受的水平，他们中的许多人会退缩到观望状态。</blockquote></p><p> I mentioned this phenomenon, referred to as the “limits to arbitrage,” in acolumn last week about the GameStop saga. Perhaps the most prominent historical example of it came at the end of the internet bubble when a number of dot-com companies with no assets, revenue or business plan were propelled to sky-high valuations. The short interest ratio actually declined from 1998 through 2000 despite ever-rising valuations.</p><p><blockquote>我在上周关于游戏驿站传奇的专栏中提到了这种被称为“套利极限”的现象。也许最突出的历史例子出现在互联网泡沫结束时，当时许多没有资产、收入或商业计划的互联网公司被推到了天价估值。尽管估值不断上升，但从1998年到2000年，空头利率实际上有所下降。</blockquote></p><p> There are some who currently believe we’re in a bubble similar to the late 1990s. If they’re right, then we should not make too much of short sellers’ lack of aggressiveness. Absent that possibility, the message of the short-sale ratio is bullish for the next 12 months.</p><p><blockquote>目前有些人认为我们正处于类似于20世纪90年代末的泡沫之中。如果他们是对的，那么我们不应该过分强调卖空者缺乏侵略性。如果没有这种可能性，卖空比率的信息在未来12个月是看涨的。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/short-sellers-were-pulling-back-even-before-reddits-gamestop-squeeze-11612233719?mod=home-page\">marketwatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9f274618dde80cee69492990094f7510","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.marketwatch.com/story/short-sellers-were-pulling-back-even-before-reddits-gamestop-squeeze-11612233719?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172237562","content_text":"Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but short-selling may be helping to keep the bull market alive.\nShort-selling, according to academic research, has strong predictive power for the U.S. stock market’s subsequent 12-month return. Right now, short interest is unusually low, says Matthew Ringgenberg, a finance professor at the University of Utah.\nRinggenberg is a leading expert on the behavior of short sellers. In an interview, he observed: “Even before the recent short squeezes, short interest in December and January was approaching historically low levels. In fact, with the exception of December 2018, this is the lowest short interest has been since before the 2008 crisis.” The data to which he is referring are plotted in the chart below.\nBe wary of contrarian investors who interpret low short interest as bearish. Ringgenberg says the contrarians are wrong; his research has found that the short sellers on balance are more right than not.\nNote carefully that the chart focuses on the raw short interest ratio. As I have reported in prior columns about Ringgenberg’s research, he has found that the predictive power of the ratio can be improved by calculating where it stands relative to its underlying trend. This adjusted ratio, he adds, is even more bullish than the raw unadjusted ratio.\nNote also that the investment horizon for which this adjusted ratio has shown explanatory power is 12 months. So even if the current prediction is spot-on, it tells us nothing about the path the market takes along the way. It could be, for example, that the S&P 500SPX,+1.39%is higher in 12 months while suffering a steep decline along the way. That’s what happened over the past year.\nOne big caveat\nRinggenberg says that on rare occasions, short sellers are particularly bearish but nevertheless choose not to aggressively sell short. This occurs most typically when investor sentiment is exuberant, the market is volatile, and when certain stocks are trading without any discernible relationship to their underlying fundamentals. During such times, he said, the already-high risks that short sellers face grow to intolerable levels—and many of them retreat to the sidelines.\nI mentioned this phenomenon, referred to as the “limits to arbitrage,” in acolumn last week about the GameStop saga. Perhaps the most prominent historical example of it came at the end of the internet bubble when a number of dot-com companies with no assets, revenue or business plan were propelled to sky-high valuations. The short interest ratio actually declined from 1998 through 2000 despite ever-rising valuations.\nThere are some who currently believe we’re in a bubble similar to the late 1990s. If they’re right, then we should not make too much of short sellers’ lack of aggressiveness. Absent that possibility, the message of the short-sale ratio is bullish for the next 12 months.","news_type":1,"symbols_score_info":{"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314143265,"gmtCreate":1612324110957,"gmtModify":1703760364604,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/314143265","repostId":"1172237562","repostType":2,"repost":{"id":"1172237562","kind":"news","pubTimestamp":1612320389,"share":"https://www.laohu8.com/m/news/1172237562?lang=zh_CN&edition=full","pubTime":"2021-02-03 10:46","market":"us","language":"en","title":"Short-sellers were pulling back even before Reddit’s GameStop squeeze<blockquote>甚至在Reddit的游戏驿站挤压之前，卖空者就已经撤退了</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172237562","media":"marketwatch","summary":"Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but shor","content":"<p>Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but short-selling may be helping to keep the bull market alive.</p><p><blockquote>GameStopGME、-60.00%和其他目标股票的卖空者最近受到了打击，但卖空可能有助于保持牛市的活力。</blockquote></p><p> Short-selling, according to academic research, has strong predictive power for the U.S. stock market’s subsequent 12-month return. Right now, short interest is unusually low, says Matthew Ringgenberg, a finance professor at the University of Utah.</p><p><blockquote>做空，根据学术研究，对美国股市随后12个月的回报有很强的预测力。犹他大学金融学教授马修·林根伯格表示，目前空头兴趣异常低。</blockquote></p><p> Ringgenberg is a leading expert on the behavior of short sellers. In an interview, he observed: “Even before the recent short squeezes, short interest in December and January was approaching historically low levels. In fact, with the exception of December 2018, this is the lowest short interest has been since before the 2008 crisis.” The data to which he is referring are plotted in the chart below.</p><p><blockquote>林根伯格是卖空者行为方面的领先专家。他在接受采访时观察到：“即使在最近的空头挤压之前，12月和1月的空头兴趣也接近历史低位。事实上，除了2018年12月，这是自2008年危机前以来空头兴趣的最低水平。”他所指的数据绘制在下图中。</blockquote></p><p> Be wary of contrarian investors who interpret low short interest as bearish. Ringgenberg says the contrarians are wrong; his research has found that the short sellers on balance are more right than not.</p><p><blockquote>警惕将空头兴趣低解读为看跌的逆向投资者。林根伯格表示，逆向投资者是错误的；他的研究发现，总的来说，卖空者是正确的。</blockquote></p><p> Note carefully that the chart focuses on the raw short interest ratio. As I have reported in prior columns about Ringgenberg’s research, he has found that the predictive power of the ratio can be improved by calculating where it stands relative to its underlying trend. This adjusted ratio, he adds, is even more bullish than the raw unadjusted ratio.</p><p><blockquote>请仔细注意，该图表重点关注原始空头利率。正如我在之前关于林根伯格研究的专栏中报道的那样，他发现可以通过计算该比率相对于其潜在趋势的位置来提高该比率的预测能力。他补充说，这一调整后的比率甚至比未经调整的原始比率更加乐观。</blockquote></p><p> Note also that the investment horizon for which this adjusted ratio has shown explanatory power is 12 months. So even if the current prediction is spot-on, it tells us nothing about the path the market takes along the way. It could be, for example, that the S&amp;P 500SPX,+1.39%is higher in 12 months while suffering a steep decline along the way. That’s what happened over the past year.</p><p><blockquote>另请注意，该调整后比率显示出解释力的投资期限为12个月。因此，即使目前的预测是准确的，它也没有告诉我们任何关于市场前进道路的信息。例如，标准普尔500SPX指数可能会在12个月内上涨+1.39%，同时在此过程中大幅下跌。这就是过去一年发生的事情。</blockquote></p><p> <b>One big caveat</b></p><p><blockquote><b>一个大警告</b></blockquote></p><p> Ringgenberg says that on rare occasions, short sellers are particularly bearish but nevertheless choose not to aggressively sell short. This occurs most typically when investor sentiment is exuberant, the market is volatile, and when certain stocks are trading without any discernible relationship to their underlying fundamentals. During such times, he said, the already-high risks that short sellers face grow to intolerable levels—and many of them retreat to the sidelines.</p><p><blockquote>林根伯格表示，在极少数情况下，卖空者特别看跌，但仍然选择不大幅卖空。当投资者情绪旺盛、市场波动以及某些股票的交易与其基本面没有任何明显关系时，这种情况最常见。他说，在这种时候，卖空者面临的本已很高的风险会增长到无法忍受的水平，他们中的许多人会退缩到观望状态。</blockquote></p><p> I mentioned this phenomenon, referred to as the “limits to arbitrage,” in acolumn last week about the GameStop saga. Perhaps the most prominent historical example of it came at the end of the internet bubble when a number of dot-com companies with no assets, revenue or business plan were propelled to sky-high valuations. The short interest ratio actually declined from 1998 through 2000 despite ever-rising valuations.</p><p><blockquote>我在上周关于游戏驿站传奇的专栏中提到了这种被称为“套利极限”的现象。也许最突出的历史例子出现在互联网泡沫结束时，当时许多没有资产、收入或商业计划的互联网公司被推到了天价估值。尽管估值不断上升，但从1998年到2000年，空头利率实际上有所下降。</blockquote></p><p> There are some who currently believe we’re in a bubble similar to the late 1990s. If they’re right, then we should not make too much of short sellers’ lack of aggressiveness. Absent that possibility, the message of the short-sale ratio is bullish for the next 12 months.</p><p><blockquote>目前有些人认为我们正处于类似于20世纪90年代末的泡沫之中。如果他们是对的，那么我们不应该过分强调卖空者缺乏侵略性。如果没有这种可能性，卖空比率的信息在未来12个月是看涨的。</blockquote></p><p></p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Short-sellers were pulling back even before Reddit’s GameStop squeeze<blockquote>甚至在Reddit的游戏驿站挤压之前，卖空者就已经撤退了</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShort-sellers were pulling back even before Reddit’s GameStop squeeze<blockquote>甚至在Reddit的游戏驿站挤压之前，卖空者就已经撤退了</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">marketwatch</strong><span class=\"h-time small\">2021-02-03 10:46</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but short-selling may be helping to keep the bull market alive.</p><p><blockquote>GameStopGME、-60.00%和其他目标股票的卖空者最近受到了打击，但卖空可能有助于保持牛市的活力。</blockquote></p><p> Short-selling, according to academic research, has strong predictive power for the U.S. stock market’s subsequent 12-month return. Right now, short interest is unusually low, says Matthew Ringgenberg, a finance professor at the University of Utah.</p><p><blockquote>做空，根据学术研究，对美国股市随后12个月的回报有很强的预测力。犹他大学金融学教授马修·林根伯格表示，目前空头兴趣异常低。</blockquote></p><p> Ringgenberg is a leading expert on the behavior of short sellers. In an interview, he observed: “Even before the recent short squeezes, short interest in December and January was approaching historically low levels. In fact, with the exception of December 2018, this is the lowest short interest has been since before the 2008 crisis.” The data to which he is referring are plotted in the chart below.</p><p><blockquote>林根伯格是卖空者行为方面的领先专家。他在接受采访时观察到：“即使在最近的空头挤压之前，12月和1月的空头兴趣也接近历史低位。事实上，除了2018年12月，这是自2008年危机前以来空头兴趣的最低水平。”他所指的数据绘制在下图中。</blockquote></p><p> Be wary of contrarian investors who interpret low short interest as bearish. Ringgenberg says the contrarians are wrong; his research has found that the short sellers on balance are more right than not.</p><p><blockquote>警惕将空头兴趣低解读为看跌的逆向投资者。林根伯格表示，逆向投资者是错误的；他的研究发现，总的来说，卖空者是正确的。</blockquote></p><p> Note carefully that the chart focuses on the raw short interest ratio. As I have reported in prior columns about Ringgenberg’s research, he has found that the predictive power of the ratio can be improved by calculating where it stands relative to its underlying trend. This adjusted ratio, he adds, is even more bullish than the raw unadjusted ratio.</p><p><blockquote>请仔细注意，该图表重点关注原始空头利率。正如我在之前关于林根伯格研究的专栏中报道的那样，他发现可以通过计算该比率相对于其潜在趋势的位置来提高该比率的预测能力。他补充说，这一调整后的比率甚至比未经调整的原始比率更加乐观。</blockquote></p><p> Note also that the investment horizon for which this adjusted ratio has shown explanatory power is 12 months. So even if the current prediction is spot-on, it tells us nothing about the path the market takes along the way. It could be, for example, that the S&amp;P 500SPX,+1.39%is higher in 12 months while suffering a steep decline along the way. That’s what happened over the past year.</p><p><blockquote>另请注意，该调整后比率显示出解释力的投资期限为12个月。因此，即使目前的预测是准确的，它也没有告诉我们任何关于市场前进道路的信息。例如，标准普尔500SPX指数可能会在12个月内上涨+1.39%，同时在此过程中大幅下跌。这就是过去一年发生的事情。</blockquote></p><p> <b>One big caveat</b></p><p><blockquote><b>一个大警告</b></blockquote></p><p> Ringgenberg says that on rare occasions, short sellers are particularly bearish but nevertheless choose not to aggressively sell short. This occurs most typically when investor sentiment is exuberant, the market is volatile, and when certain stocks are trading without any discernible relationship to their underlying fundamentals. During such times, he said, the already-high risks that short sellers face grow to intolerable levels—and many of them retreat to the sidelines.</p><p><blockquote>林根伯格表示，在极少数情况下，卖空者特别看跌，但仍然选择不大幅卖空。当投资者情绪旺盛、市场波动以及某些股票的交易与其基本面没有任何明显关系时，这种情况最常见。他说，在这种时候，卖空者面临的本已很高的风险会增长到无法忍受的水平，他们中的许多人会退缩到观望状态。</blockquote></p><p> I mentioned this phenomenon, referred to as the “limits to arbitrage,” in acolumn last week about the GameStop saga. Perhaps the most prominent historical example of it came at the end of the internet bubble when a number of dot-com companies with no assets, revenue or business plan were propelled to sky-high valuations. The short interest ratio actually declined from 1998 through 2000 despite ever-rising valuations.</p><p><blockquote>我在上周关于游戏驿站传奇的专栏中提到了这种被称为“套利极限”的现象。也许最突出的历史例子出现在互联网泡沫结束时，当时许多没有资产、收入或商业计划的互联网公司被推到了天价估值。尽管估值不断上升，但从1998年到2000年，空头利率实际上有所下降。</blockquote></p><p> There are some who currently believe we’re in a bubble similar to the late 1990s. If they’re right, then we should not make too much of short sellers’ lack of aggressiveness. Absent that possibility, the message of the short-sale ratio is bullish for the next 12 months.</p><p><blockquote>目前有些人认为我们正处于类似于20世纪90年代末的泡沫之中。如果他们是对的，那么我们不应该过分强调卖空者缺乏侵略性。如果没有这种可能性，卖空比率的信息在未来12个月是看涨的。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.marketwatch.com/story/short-sellers-were-pulling-back-even-before-reddits-gamestop-squeeze-11612233719?mod=home-page\">marketwatch</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9f274618dde80cee69492990094f7510","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://www.marketwatch.com/story/short-sellers-were-pulling-back-even-before-reddits-gamestop-squeeze-11612233719?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172237562","content_text":"Short-sellers in GameStopGME,-60.00%and other targeted stocks have been beaten up recently, but short-selling may be helping to keep the bull market alive.\nShort-selling, according to academic research, has strong predictive power for the U.S. stock market’s subsequent 12-month return. Right now, short interest is unusually low, says Matthew Ringgenberg, a finance professor at the University of Utah.\nRinggenberg is a leading expert on the behavior of short sellers. In an interview, he observed: “Even before the recent short squeezes, short interest in December and January was approaching historically low levels. In fact, with the exception of December 2018, this is the lowest short interest has been since before the 2008 crisis.” The data to which he is referring are plotted in the chart below.\nBe wary of contrarian investors who interpret low short interest as bearish. Ringgenberg says the contrarians are wrong; his research has found that the short sellers on balance are more right than not.\nNote carefully that the chart focuses on the raw short interest ratio. As I have reported in prior columns about Ringgenberg’s research, he has found that the predictive power of the ratio can be improved by calculating where it stands relative to its underlying trend. This adjusted ratio, he adds, is even more bullish than the raw unadjusted ratio.\nNote also that the investment horizon for which this adjusted ratio has shown explanatory power is 12 months. So even if the current prediction is spot-on, it tells us nothing about the path the market takes along the way. It could be, for example, that the S&P 500SPX,+1.39%is higher in 12 months while suffering a steep decline along the way. That’s what happened over the past year.\nOne big caveat\nRinggenberg says that on rare occasions, short sellers are particularly bearish but nevertheless choose not to aggressively sell short. This occurs most typically when investor sentiment is exuberant, the market is volatile, and when certain stocks are trading without any discernible relationship to their underlying fundamentals. During such times, he said, the already-high risks that short sellers face grow to intolerable levels—and many of them retreat to the sidelines.\nI mentioned this phenomenon, referred to as the “limits to arbitrage,” in acolumn last week about the GameStop saga. Perhaps the most prominent historical example of it came at the end of the internet bubble when a number of dot-com companies with no assets, revenue or business plan were propelled to sky-high valuations. The short interest ratio actually declined from 1998 through 2000 despite ever-rising valuations.\nThere are some who currently believe we’re in a bubble similar to the late 1990s. If they’re right, then we should not make too much of short sellers’ lack of aggressiveness. Absent that possibility, the message of the short-sale ratio is bullish for the next 12 months.","news_type":1,"symbols_score_info":{"GME":0.9}},"isVote":1,"tweetType":1,"viewCount":508,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":315879851,"gmtCreate":1612236456273,"gmtModify":1703759132698,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315879851","repostId":"1155510692","repostType":4,"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":315870726,"gmtCreate":1612236385565,"gmtModify":1703759132010,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Indeed","listText":"Indeed","text":"Indeed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315870726","repostId":"1109554256","repostType":4,"isVote":1,"tweetType":1,"viewCount":582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":116568006,"gmtCreate":1622812572205,"gmtModify":1634097783234,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/116568006","repostId":"1122373606","repostType":4,"repost":{"id":"1122373606","kind":"news","pubTimestamp":1622793373,"share":"https://www.laohu8.com/m/news/1122373606?lang=zh_CN&edition=full","pubTime":"2021-06-04 15:56","market":"us","language":"en","title":"Where Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122373606","media":"seekingalpha","summary":"Summary\n\nApple has been a great investment over the last decade, but the next decade may look quite ","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has been a great investment over the last decade, but the next decade may look quite different.</li>  <li>Apple has seen its growth slow down over the last decade, and it will likely not be a growth monster in the coming years, either.</li>  <li>Shares have ample long-term upside, but investors should consider the current valuation before jumping to decisions.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f2ea192ed76d9772c2c6a820098faf5\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>Photo by Paopano/iStock Editorial via Getty Images</span></p><p><blockquote><ul><li>苹果在过去十年中是一项伟大的投资，但下一个十年可能会大不相同。</li><li>苹果的增长在过去十年中有所放缓，未来几年也可能不会成为增长怪物。</li><li>股价具有充足的长期上涨空间，但投资者在做出决定之前应考虑当前的估值。</li></ul><p class=\"t-img-caption\"><span>摄影：Paopano/iStock社论，来自Getty Images</span></p></blockquote></p><p> <b>Article Thesis</b></p><p><blockquote><b>文章论文</b></blockquote></p><p> Apple (AAPL) has been one of the best investments one could have made over the last decade. Over the next decade, its growth may not be the same, however. Yet, thanks to massive shareholder return programs and a move towards services, Apple's stock will likely still be significantly higher a decade from now - even though the current valuation is rather high.</p><p><blockquote>苹果（AAPL）是过去十年中最好的投资之一。然而，在接下来的十年里，它的增长可能会有所不同。然而，由于大规模的股东回报计划和向服务业的转变，苹果的股价在十年后仍可能大幅上涨——尽管目前的估值相当高。</blockquote></p><p> <b>Apple Stock Price</b></p><p><blockquote><b>苹果股价</b></blockquote></p><p> Over the last decade, Apple Inc. has been a great investment:</p><p><blockquote>在过去十年中，苹果公司一直是一项伟大的投资：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d29aa34bdbc5bab7d0730a4095954e6\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares have returned 900% in those ten years, before dividends, for a compounded annual return of approximately 26%, easily trouncing the returns of the broad market during that time frame. Importantly, shares have risen a lot more than the company's market capitalization, which grew by only 550% over the last decade. The difference can be explained by the company's large share repurchase programs, which have lowered the share count drastically over the last decade. The last decade, of course, was a highly successful period for Apple on a business basis, as the company benefited from the rise of smartphones while also having success with new products such as its Watch and tablets, which Apple more or less introduced as a new product category. Right now, shares trade for $125, up 57% over the last twelve months, but down 6% in 2021 to date. Following strong gains during 2020, shares seem to be in a consolidation pattern for now, which is not too much of a surprise, as Apple's valuation had expanded a lot in the recent past, and it seems that the company's business growth has to catch up to the recent share price increases now. The current consensus price target is $156, which implies an upside potential of 25%. Since there are no signs of shares leaving their current trading range right now, I personally do not think that Apple will breach $150 in the near term.</p><p><blockquote>在这十年中，扣除股息前，股票回报率为900%，复合年回报率约为26%，轻松击败了同期大盘的回报率。重要的是，该公司股价的涨幅远远超过了该公司的市值，而该公司的市值在过去十年中仅增长了550%。这种差异可以用该公司的大规模股票回购计划来解释，该计划在过去十年中大幅减少了股票数量。当然，过去十年对苹果来说是一个商业上非常成功的时期，因为该公司受益于智能手机的兴起，同时也在手表和平板电脑等新产品上取得了成功，苹果或多或少地将其作为一个新产品类别推出。目前，股价为125美元，过去12个月上涨57%，但2021年迄今下跌6%。继2020年强劲上涨之后，股价目前似乎处于盘整格局，这并不令人意外，因为苹果的估值最近已经扩大了很多，而且该公司的业务增长似乎必须赶上最近的股价上涨。目前的一致目标价为156美元，这意味着25%的上涨潜力。由于目前没有迹象表明股价会离开当前的交易区间，我个人认为苹果短期内不会突破150美元。</blockquote></p><p> <b>Where Will Apple Stock Be In 10 Years</b></p><p><blockquote><b>10年后苹果股票会在哪里</b></blockquote></p><p> Apple's stock price in 2031 is, of course, nothing that can be forecasted with any precision. As history has shown, again and again, it is not even possible to forecast share prices precisely over a much shorter period of time. It is, however, possible to craft scenarios to see where share prices could be in the future under certain conditions, to get a feel for what might be a reasonable expectation for the future.</p><p><blockquote>当然，苹果2031年的股价是无法准确预测的。正如历史一次又一次地表明的那样，甚至不可能在更短的时间内准确预测股价。然而，可以设计情景来了解在某些条件下未来股价的走势，从而了解对未来的合理预期。</blockquote></p><p> To craft one such scenario, we have to consider Apple's business growth, Apple's shareholder return program, and the valuation multiple that shares might trade at in the future.</p><p><blockquote>为了构建这样的场景，我们必须考虑苹果的业务增长、苹果的股东回报计划以及股票未来可能交易的估值倍数。</blockquote></p><p> <b>Apple's business growth</b></p><p><blockquote><b>苹果的业务增长</b></blockquote></p><p> Apple Inc. has seen years of stronger growth and years of weaker growth in the past. This mostly can be explained by factors such as new product introductions, e.g. Watch or iPad, and by the strength of the respective current iPhone models, which see varying demand depending on the year. Other factors, such as economic growth or trade issues, play a role as well.</p><p><blockquote>苹果公司过去曾经历过多年的强劲增长和多年的疲软增长。这主要可以用新产品推出等因素来解释，例如。手表或iPad，以及各自当前iPhone型号的强度，这些型号的需求因年份而异。其他因素，如经济增长或贸易问题，也发挥了作用。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5b8bd8ef6cdaa13850c1380e870554c\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Overall, revenues have grown by 154% over the last decade, but as we see in the above chart, revenue growth has been relatively uneven. During the early 2010s, Apple generated massive growth on the back of the iPhones \"road to victory\", whereas revenue growth declined to a much slower pace in the following years. There were even some years during which revenues declined on a year-over-year basis, such as 2016. The average annual revenue growth pace was 10% over the last decade, but when we factor in that this was lifted up by the very strong growth in 2011 and 2012, it may not be too reasonable to assume that Apple will grow by 10% a year in the future, too. Investors should also consider that maintaining a high growth rate becomes ever more difficult the larger a company gets. This does, however, not mean that Apple's revenue growth will slow down to zero.</p><p><blockquote>总体而言，过去十年收入增长了154%，但正如我们在上图中看到的，收入增长相对不均衡。2010年代初，苹果凭借iPhone的“胜利之路”实现了巨大增长，而在接下来的几年里，收入增长速度放缓。甚至有一些年份的收入同比下降，例如2016年。过去十年的平均年收入增长率为10%，但当我们考虑到2011年和2012年的强劲增长推动了这一增长率时，假设苹果将增长10%可能不太合理。未来一年也是如此。投资者还应该考虑到，公司规模越大，保持高增长率就变得越困难。然而，这并不意味着苹果的收入增长将放缓至零。</blockquote></p><p></p><p> On the back of price increases for its products and the potential for market share gains in&nbsp;high-growth countries such as China, where more and more people will be able to buy Apple's higher-priced products, it seems reasonable to assume that Apple will generate at least some growth from its core businesses. Add in growth in the services segment - people use their phones more and more, which should lead to higher app spending - and consider the potential for new product launches (although I assume none will be as massive as the iPhone), and Apple should be able to grow its business at a solid pace. I personally assume that a 5%-7% revenue growth rate could be a realistic estimate for the coming years, although some readers will of course have different opinions.</p><p><blockquote>在其产品价格上涨以及中国等高增长国家市场份额增长的潜力（越来越多的人将能够购买苹果价格较高的产品）的背景下，似乎有理由假设苹果将至少从其核心业务中产生一些增长。再加上服务领域的增长——人们越来越多地使用手机，这应该会导致更高的应用支出——并考虑新产品发布的潜力（尽管我认为没有一款产品会像iPhone那样庞大），苹果应该能够以稳健的速度发展其业务。我个人认为5%-7%的收入增长率可能是未来几年的现实估计，尽管一些读者当然会有不同的意见。</blockquote></p><p> <b>Apple's shareholder returns</b></p><p><blockquote><b>苹果的股东回报</b></blockquote></p><p> Apple has lowered its share count massively in the past, as shown above, and it is, I believe, reasonable to assume that the same will happen going forward. Over the last decade, Apple bought back 36% of its shares. If the same were to happen over the next decade, each remaining share's portion of the company's value would rise by 56%, or 4.6% annualized. Due to the fact that Apple's current valuation is significantly higher than its historic valuation, buybacks could be less impactful in the future, though. Apple has, for example, only reduced its share count by 2.6% over the last year.</p><p><blockquote>如上所示，苹果过去曾大幅减少其股票数量，我相信，有理由假设未来也会发生同样的情况。过去十年，苹果回购了36%的股份。如果未来十年发生同样的情况，每股剩余股票在公司价值中的份额将上涨56%，即年化4.6%。不过，由于苹果目前的估值明显高于其历史估值，回购在未来的影响可能会较小。例如，苹果去年的股票数量仅减少了2.6%。</blockquote></p><p> This is why I believe that the share count will not decline by another 36% over the coming decade. When we adjust that downward to 25%, this would result in a ~3% annual tailwind for Apple's growth when we look at per-share metrics, which are the deciding factor for Apple's share price growth. Combined with my 5%-7% business growth estimate, I thus assume that Apple will grow by 8%-10% on a per-share basis in the long term.</p><p><blockquote>这就是为什么我相信未来十年股票数量不会再下降36%。当我们将其向下调整至25%时，当我们考虑每股指标时，这将为苹果的增长带来约3%的年度推动力，而每股指标是苹果股价增长的决定性因素。结合我5%-7%的业务增长预测，我因此假设苹果的每股长期增长将达到8%-10%。</blockquote></p><p> <b>Apple's future valuation</b></p><p><blockquote><b>苹果的未来估值</b></blockquote></p><p> AAPL has been valued in a very wide range in the past, seeing its shares trade for very low multiples at some points, whereas investors were willing to pay significantly more at other times:</p><p><blockquote>苹果公司过去的估值范围很广，其股票在某些时候的市盈率非常低，而投资者在其他时候愿意支付更高的价格：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be5cb8bbc04ff0e0a13ee64f6f2bd90a\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares could, five years ago, be bought for a very low 10x net earnings, which naturally was a great time to enter or expand positions. In late 2020, however, shares were trading for as much as 40x the company's net earnings, which seems like a quite high valuation. Right now, AAPL trades at 28x trailing earnings, and at around 24x forward profits. In the above chart, we also see the median earnings multiples over the last 3, 5, 7, and 10 years. It is pretty clear that Apple's valuation has expanded over the years, which is why the median values are higher for the shorter \"lookback\" periods. I do not believe that AAPL will trade at the 15.5x net earnings that it has traded at, on average, over the last decade, as this seems like a rather low valuation for a quality company like Apple with a strong brand, massive scale, great margins, and a fortress balance sheet. On the other hand, I also don't believe that Apple will trade at a 24-28x earnings multiple forever - for a company that generates solid but unspectacular business growth in the mid-single-digits, that seems quite expensive. This is especially true when we consider that interest rates will likely be higher a decade from now, which should pressure valuations for all equities, all else equal. I thus believe that a valuation of around 20x net earnings could be a reasonable estimate for 2031, which would be more or less in line with the 3-year median earnings multiple.</p><p><blockquote>五年前，可以以非常低的10倍净利润购买股票，这自然是进入或扩大头寸的好时机。然而，2020年底，该公司的股价高达该公司净利润的40倍，这似乎是一个相当高的估值。目前，AAPL的往绩市盈率为28倍，远期利润约为24倍。在上图中，我们还看到了过去3年、5年、7年和10年的市盈率中位数。很明显，苹果的估值多年来一直在扩大，这就是为什么在较短的“回顾”期内中值较高。我不认为AAPL的市盈率会达到过去十年平均市盈率的15.5倍，因为对于像苹果这样拥有强大品牌、庞大规模的优质公司来说，这似乎是一个相当低的估值。、巨大的利润和堡垒般的资产负债表。另一方面，我也不相信苹果的市盈率会永远保持在24-28倍——对于一家业务增长稳健但不引人注目的中个位数的公司来说，这似乎相当昂贵。当我们考虑到十年后利率可能会更高时，尤其如此，在其他条件相同的情况下，这应该会给所有股票的估值带来压力。因此，我认为2031年净利润20倍左右的估值可能是合理的估计，这或多或少与3年市盈率中位数一致。</blockquote></p><p> <b>Is AAPL A Buy Or Sell Now</b></p><p><blockquote><b>AAPL现在是买入还是卖出</b></blockquote></p><p> Starting our calculation with an EPS estimate of $5.15 for 2021 and assuming that this will grow by 7%-10% a year through 2031, we reach an EPS range of $10.10 to $13.40. Putting a 20x earnings multiple on that leads to a target price of around $200-$270/share. At the midpoint of around $235, shares would thus see gains of around 90% from the current level, or around 6.5% annualized. That surely is not a bad return, and when we add in the dividend, we would get to an annualized return of roughly 7%. This is, on the other hand, also not an outrageously great return, I believe.</p><p><blockquote>从2021年每股收益估计为5.15美元开始计算，并假设到2031年每年增长7%-10%，我们的每股收益范围为10.10美元至13.40美元。将市盈率定为20倍，目标价约为每股200-270美元。因此，在235美元左右的中点，股价将较当前水平上涨约90%，年化涨幅约为6.5%。这肯定是一个不错的回报，当我们加上股息时，我们将获得大约7%的年化回报率。另一方面，我相信这也不是一个惊人的回报。</blockquote></p><p></p><p> AAPL has, I believe, significant upside potential over the next decade, but that should not be a large surprise - many companies will see significant growth over a time span this long. I personally am not too excited about a 7% expected long-term return. When we consider that shares do have considerable downside risk in the next 1-3 years if Apple's valuation declines, e.g. due to rising interest rates, it may be a better choice to stay on the sidelines for now. Long-term investors will likely not do badly when they buy shares at current levels, but they will likely also not do great. For now, I'd rate Apple a hold, and a potential buy if its valuation comes closer to the longer-term average. Those that are more optimistic about new product launches may disagree and favor buying here, but it could turn out that waiting for a better opportunity is the best choice here.</p><p><blockquote>我相信，苹果公司在未来十年具有巨大的上涨潜力，但这并不令人意外——许多公司将在这么长的时间内实现显着增长。我个人对7%的预期长期回报率不太兴奋。当我们考虑到，如果苹果的估值下降，例如由于利率上升，股价在未来1-3年内确实存在相当大的下行风险，目前保持观望可能是更好的选择。长期投资者在当前水平购买股票时可能不会表现不佳，但也可能不会表现出色。目前，我对苹果的评级为持有，如果其估值接近长期平均水平，则可能买入。那些对新产品发布更乐观的人可能不同意并倾向于在这里购买，但事实证明，等待更好的机会是这里的最佳选择。</blockquote></p><p> Summing it up, I'd say shares do have significant upside potential over the next decade, but the upside potential is not large enough to make me buy shares at current, elevated, valuations.</p><p><blockquote>总而言之，我想说，该股在未来十年确实有巨大的上涨潜力，但上涨潜力还不足以让我以当前较高的估值购买股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Where Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhere Will Apple Stock Be In 10 Years? What To Consider<blockquote>10年后苹果股票会在哪里？要考虑什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-06-04 15:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has been a great investment over the last decade, but the next decade may look quite different.</li>  <li>Apple has seen its growth slow down over the last decade, and it will likely not be a growth monster in the coming years, either.</li>  <li>Shares have ample long-term upside, but investors should consider the current valuation before jumping to decisions.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f2ea192ed76d9772c2c6a820098faf5\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>Photo by Paopano/iStock Editorial via Getty Images</span></p><p><blockquote><ul><li>苹果在过去十年中是一项伟大的投资，但下一个十年可能会大不相同。</li><li>苹果的增长在过去十年中有所放缓，未来几年也可能不会成为增长怪物。</li><li>股价具有充足的长期上涨空间，但投资者在做出决定之前应考虑当前的估值。</li></ul><p class=\"t-img-caption\"><span>摄影：Paopano/iStock社论，来自Getty Images</span></p></blockquote></p><p> <b>Article Thesis</b></p><p><blockquote><b>文章论文</b></blockquote></p><p> Apple (AAPL) has been one of the best investments one could have made over the last decade. Over the next decade, its growth may not be the same, however. Yet, thanks to massive shareholder return programs and a move towards services, Apple's stock will likely still be significantly higher a decade from now - even though the current valuation is rather high.</p><p><blockquote>苹果（AAPL）是过去十年中最好的投资之一。然而，在接下来的十年里，它的增长可能会有所不同。然而，由于大规模的股东回报计划和向服务业的转变，苹果的股价在十年后仍可能大幅上涨——尽管目前的估值相当高。</blockquote></p><p> <b>Apple Stock Price</b></p><p><blockquote><b>苹果股价</b></blockquote></p><p> Over the last decade, Apple Inc. has been a great investment:</p><p><blockquote>在过去十年中，苹果公司一直是一项伟大的投资：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5d29aa34bdbc5bab7d0730a4095954e6\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares have returned 900% in those ten years, before dividends, for a compounded annual return of approximately 26%, easily trouncing the returns of the broad market during that time frame. Importantly, shares have risen a lot more than the company's market capitalization, which grew by only 550% over the last decade. The difference can be explained by the company's large share repurchase programs, which have lowered the share count drastically over the last decade. The last decade, of course, was a highly successful period for Apple on a business basis, as the company benefited from the rise of smartphones while also having success with new products such as its Watch and tablets, which Apple more or less introduced as a new product category. Right now, shares trade for $125, up 57% over the last twelve months, but down 6% in 2021 to date. Following strong gains during 2020, shares seem to be in a consolidation pattern for now, which is not too much of a surprise, as Apple's valuation had expanded a lot in the recent past, and it seems that the company's business growth has to catch up to the recent share price increases now. The current consensus price target is $156, which implies an upside potential of 25%. Since there are no signs of shares leaving their current trading range right now, I personally do not think that Apple will breach $150 in the near term.</p><p><blockquote>在这十年中，扣除股息前，股票回报率为900%，复合年回报率约为26%，轻松击败了同期大盘的回报率。重要的是，该公司股价的涨幅远远超过了该公司的市值，而该公司的市值在过去十年中仅增长了550%。这种差异可以用该公司的大规模股票回购计划来解释，该计划在过去十年中大幅减少了股票数量。当然，过去十年对苹果来说是一个商业上非常成功的时期，因为该公司受益于智能手机的兴起，同时也在手表和平板电脑等新产品上取得了成功，苹果或多或少地将其作为一个新产品类别推出。目前，股价为125美元，过去12个月上涨57%，但2021年迄今下跌6%。继2020年强劲上涨之后，股价目前似乎处于盘整格局，这并不令人意外，因为苹果的估值最近已经扩大了很多，而且该公司的业务增长似乎必须赶上最近的股价上涨。目前的一致目标价为156美元，这意味着25%的上涨潜力。由于目前没有迹象表明股价会离开当前的交易区间，我个人认为苹果短期内不会突破150美元。</blockquote></p><p> <b>Where Will Apple Stock Be In 10 Years</b></p><p><blockquote><b>10年后苹果股票会在哪里</b></blockquote></p><p> Apple's stock price in 2031 is, of course, nothing that can be forecasted with any precision. As history has shown, again and again, it is not even possible to forecast share prices precisely over a much shorter period of time. It is, however, possible to craft scenarios to see where share prices could be in the future under certain conditions, to get a feel for what might be a reasonable expectation for the future.</p><p><blockquote>当然，苹果2031年的股价是无法准确预测的。正如历史一次又一次地表明的那样，甚至不可能在更短的时间内准确预测股价。然而，可以设计情景来了解在某些条件下未来股价的走势，从而了解对未来的合理预期。</blockquote></p><p> To craft one such scenario, we have to consider Apple's business growth, Apple's shareholder return program, and the valuation multiple that shares might trade at in the future.</p><p><blockquote>为了构建这样的场景，我们必须考虑苹果的业务增长、苹果的股东回报计划以及股票未来可能交易的估值倍数。</blockquote></p><p> <b>Apple's business growth</b></p><p><blockquote><b>苹果的业务增长</b></blockquote></p><p> Apple Inc. has seen years of stronger growth and years of weaker growth in the past. This mostly can be explained by factors such as new product introductions, e.g. Watch or iPad, and by the strength of the respective current iPhone models, which see varying demand depending on the year. Other factors, such as economic growth or trade issues, play a role as well.</p><p><blockquote>苹果公司过去曾经历过多年的强劲增长和多年的疲软增长。这主要可以用新产品推出等因素来解释，例如。手表或iPad，以及各自当前iPhone型号的强度，这些型号的需求因年份而异。其他因素，如经济增长或贸易问题，也发挥了作用。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a5b8bd8ef6cdaa13850c1380e870554c\" tg-width=\"635\" tg-height=\"419\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Overall, revenues have grown by 154% over the last decade, but as we see in the above chart, revenue growth has been relatively uneven. During the early 2010s, Apple generated massive growth on the back of the iPhones \"road to victory\", whereas revenue growth declined to a much slower pace in the following years. There were even some years during which revenues declined on a year-over-year basis, such as 2016. The average annual revenue growth pace was 10% over the last decade, but when we factor in that this was lifted up by the very strong growth in 2011 and 2012, it may not be too reasonable to assume that Apple will grow by 10% a year in the future, too. Investors should also consider that maintaining a high growth rate becomes ever more difficult the larger a company gets. This does, however, not mean that Apple's revenue growth will slow down to zero.</p><p><blockquote>总体而言，过去十年收入增长了154%，但正如我们在上图中看到的，收入增长相对不均衡。2010年代初，苹果凭借iPhone的“胜利之路”实现了巨大增长，而在接下来的几年里，收入增长速度放缓。甚至有一些年份的收入同比下降，例如2016年。过去十年的平均年收入增长率为10%，但当我们考虑到2011年和2012年的强劲增长推动了这一增长率时，假设苹果将增长10%可能不太合理。未来一年也是如此。投资者还应该考虑到，公司规模越大，保持高增长率就变得越困难。然而，这并不意味着苹果的收入增长将放缓至零。</blockquote></p><p></p><p> On the back of price increases for its products and the potential for market share gains in&nbsp;high-growth countries such as China, where more and more people will be able to buy Apple's higher-priced products, it seems reasonable to assume that Apple will generate at least some growth from its core businesses. Add in growth in the services segment - people use their phones more and more, which should lead to higher app spending - and consider the potential for new product launches (although I assume none will be as massive as the iPhone), and Apple should be able to grow its business at a solid pace. I personally assume that a 5%-7% revenue growth rate could be a realistic estimate for the coming years, although some readers will of course have different opinions.</p><p><blockquote>在其产品价格上涨以及中国等高增长国家市场份额增长的潜力（越来越多的人将能够购买苹果价格较高的产品）的背景下，似乎有理由假设苹果将至少从其核心业务中产生一些增长。再加上服务领域的增长——人们越来越多地使用手机，这应该会导致更高的应用支出——并考虑新产品发布的潜力（尽管我认为没有一款产品会像iPhone那样庞大），苹果应该能够以稳健的速度发展其业务。我个人认为5%-7%的收入增长率可能是未来几年的现实估计，尽管一些读者当然会有不同的意见。</blockquote></p><p> <b>Apple's shareholder returns</b></p><p><blockquote><b>苹果的股东回报</b></blockquote></p><p> Apple has lowered its share count massively in the past, as shown above, and it is, I believe, reasonable to assume that the same will happen going forward. Over the last decade, Apple bought back 36% of its shares. If the same were to happen over the next decade, each remaining share's portion of the company's value would rise by 56%, or 4.6% annualized. Due to the fact that Apple's current valuation is significantly higher than its historic valuation, buybacks could be less impactful in the future, though. Apple has, for example, only reduced its share count by 2.6% over the last year.</p><p><blockquote>如上所示，苹果过去曾大幅减少其股票数量，我相信，有理由假设未来也会发生同样的情况。过去十年，苹果回购了36%的股份。如果未来十年发生同样的情况，每股剩余股票在公司价值中的份额将上涨56%，即年化4.6%。不过，由于苹果目前的估值明显高于其历史估值，回购在未来的影响可能会较小。例如，苹果去年的股票数量仅减少了2.6%。</blockquote></p><p> This is why I believe that the share count will not decline by another 36% over the coming decade. When we adjust that downward to 25%, this would result in a ~3% annual tailwind for Apple's growth when we look at per-share metrics, which are the deciding factor for Apple's share price growth. Combined with my 5%-7% business growth estimate, I thus assume that Apple will grow by 8%-10% on a per-share basis in the long term.</p><p><blockquote>这就是为什么我相信未来十年股票数量不会再下降36%。当我们将其向下调整至25%时，当我们考虑每股指标时，这将为苹果的增长带来约3%的年度推动力，而每股指标是苹果股价增长的决定性因素。结合我5%-7%的业务增长预测，我因此假设苹果的每股长期增长将达到8%-10%。</blockquote></p><p> <b>Apple's future valuation</b></p><p><blockquote><b>苹果的未来估值</b></blockquote></p><p> AAPL has been valued in a very wide range in the past, seeing its shares trade for very low multiples at some points, whereas investors were willing to pay significantly more at other times:</p><p><blockquote>苹果公司过去的估值范围很广，其股票在某些时候的市盈率非常低，而投资者在其他时候愿意支付更高的价格：</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/be5cb8bbc04ff0e0a13ee64f6f2bd90a\" tg-width=\"635\" tg-height=\"470\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Shares could, five years ago, be bought for a very low 10x net earnings, which naturally was a great time to enter or expand positions. In late 2020, however, shares were trading for as much as 40x the company's net earnings, which seems like a quite high valuation. Right now, AAPL trades at 28x trailing earnings, and at around 24x forward profits. In the above chart, we also see the median earnings multiples over the last 3, 5, 7, and 10 years. It is pretty clear that Apple's valuation has expanded over the years, which is why the median values are higher for the shorter \"lookback\" periods. I do not believe that AAPL will trade at the 15.5x net earnings that it has traded at, on average, over the last decade, as this seems like a rather low valuation for a quality company like Apple with a strong brand, massive scale, great margins, and a fortress balance sheet. On the other hand, I also don't believe that Apple will trade at a 24-28x earnings multiple forever - for a company that generates solid but unspectacular business growth in the mid-single-digits, that seems quite expensive. This is especially true when we consider that interest rates will likely be higher a decade from now, which should pressure valuations for all equities, all else equal. I thus believe that a valuation of around 20x net earnings could be a reasonable estimate for 2031, which would be more or less in line with the 3-year median earnings multiple.</p><p><blockquote>五年前，可以以非常低的10倍净利润购买股票，这自然是进入或扩大头寸的好时机。然而，2020年底，该公司的股价高达该公司净利润的40倍，这似乎是一个相当高的估值。目前，AAPL的往绩市盈率为28倍，远期利润约为24倍。在上图中，我们还看到了过去3年、5年、7年和10年的市盈率中位数。很明显，苹果的估值多年来一直在扩大，这就是为什么在较短的“回顾”期内中值较高。我不认为AAPL的市盈率会达到过去十年平均市盈率的15.5倍，因为对于像苹果这样拥有强大品牌、庞大规模的优质公司来说，这似乎是一个相当低的估值。、巨大的利润和堡垒般的资产负债表。另一方面，我也不相信苹果的市盈率会永远保持在24-28倍——对于一家业务增长稳健但不引人注目的中个位数的公司来说，这似乎相当昂贵。当我们考虑到十年后利率可能会更高时，尤其如此，在其他条件相同的情况下，这应该会给所有股票的估值带来压力。因此，我认为2031年净利润20倍左右的估值可能是合理的估计，这或多或少与3年市盈率中位数一致。</blockquote></p><p> <b>Is AAPL A Buy Or Sell Now</b></p><p><blockquote><b>AAPL现在是买入还是卖出</b></blockquote></p><p> Starting our calculation with an EPS estimate of $5.15 for 2021 and assuming that this will grow by 7%-10% a year through 2031, we reach an EPS range of $10.10 to $13.40. Putting a 20x earnings multiple on that leads to a target price of around $200-$270/share. At the midpoint of around $235, shares would thus see gains of around 90% from the current level, or around 6.5% annualized. That surely is not a bad return, and when we add in the dividend, we would get to an annualized return of roughly 7%. This is, on the other hand, also not an outrageously great return, I believe.</p><p><blockquote>从2021年每股收益估计为5.15美元开始计算，并假设到2031年每年增长7%-10%，我们的每股收益范围为10.10美元至13.40美元。将市盈率定为20倍，目标价约为每股200-270美元。因此，在235美元左右的中点，股价将较当前水平上涨约90%，年化涨幅约为6.5%。这肯定是一个不错的回报，当我们加上股息时，我们将获得大约7%的年化回报率。另一方面，我相信这也不是一个惊人的回报。</blockquote></p><p></p><p> AAPL has, I believe, significant upside potential over the next decade, but that should not be a large surprise - many companies will see significant growth over a time span this long. I personally am not too excited about a 7% expected long-term return. When we consider that shares do have considerable downside risk in the next 1-3 years if Apple's valuation declines, e.g. due to rising interest rates, it may be a better choice to stay on the sidelines for now. Long-term investors will likely not do badly when they buy shares at current levels, but they will likely also not do great. For now, I'd rate Apple a hold, and a potential buy if its valuation comes closer to the longer-term average. Those that are more optimistic about new product launches may disagree and favor buying here, but it could turn out that waiting for a better opportunity is the best choice here.</p><p><blockquote>我相信，苹果公司在未来十年具有巨大的上涨潜力，但这并不令人意外——许多公司将在这么长的时间内实现显着增长。我个人对7%的预期长期回报率不太兴奋。当我们考虑到，如果苹果的估值下降，例如由于利率上升，股价在未来1-3年内确实存在相当大的下行风险，目前保持观望可能是更好的选择。长期投资者在当前水平购买股票时可能不会表现不佳，但也可能不会表现出色。目前，我对苹果的评级为持有，如果其估值接近长期平均水平，则可能买入。那些对新产品发布更乐观的人可能不同意并倾向于在这里购买，但事实证明，等待更好的机会是这里的最佳选择。</blockquote></p><p> Summing it up, I'd say shares do have significant upside potential over the next decade, but the upside potential is not large enough to make me buy shares at current, elevated, valuations.</p><p><blockquote>总而言之，我想说，该股在未来十年确实有巨大的上涨潜力，但上涨潜力还不足以让我以当前较高的估值购买股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4432703-apple-stock-in-10-years\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4432703-apple-stock-in-10-years","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122373606","content_text":"Summary\n\nApple has been a great investment over the last decade, but the next decade may look quite different.\nApple has seen its growth slow down over the last decade, and it will likely not be a growth monster in the coming years, either.\nShares have ample long-term upside, but investors should consider the current valuation before jumping to decisions.\n\nPhoto by Paopano/iStock Editorial via Getty Images\nArticle Thesis\nApple (AAPL) has been one of the best investments one could have made over the last decade. Over the next decade, its growth may not be the same, however. Yet, thanks to massive shareholder return programs and a move towards services, Apple's stock will likely still be significantly higher a decade from now - even though the current valuation is rather high.\nApple Stock Price\nOver the last decade, Apple Inc. has been a great investment:\nData by YCharts\nShares have returned 900% in those ten years, before dividends, for a compounded annual return of approximately 26%, easily trouncing the returns of the broad market during that time frame. Importantly, shares have risen a lot more than the company's market capitalization, which grew by only 550% over the last decade. The difference can be explained by the company's large share repurchase programs, which have lowered the share count drastically over the last decade. The last decade, of course, was a highly successful period for Apple on a business basis, as the company benefited from the rise of smartphones while also having success with new products such as its Watch and tablets, which Apple more or less introduced as a new product category. Right now, shares trade for $125, up 57% over the last twelve months, but down 6% in 2021 to date. Following strong gains during 2020, shares seem to be in a consolidation pattern for now, which is not too much of a surprise, as Apple's valuation had expanded a lot in the recent past, and it seems that the company's business growth has to catch up to the recent share price increases now. The current consensus price target is $156, which implies an upside potential of 25%. Since there are no signs of shares leaving their current trading range right now, I personally do not think that Apple will breach $150 in the near term.\nWhere Will Apple Stock Be In 10 Years\nApple's stock price in 2031 is, of course, nothing that can be forecasted with any precision. As history has shown, again and again, it is not even possible to forecast share prices precisely over a much shorter period of time. It is, however, possible to craft scenarios to see where share prices could be in the future under certain conditions, to get a feel for what might be a reasonable expectation for the future.\nTo craft one such scenario, we have to consider Apple's business growth, Apple's shareholder return program, and the valuation multiple that shares might trade at in the future.\nApple's business growth\nApple Inc. has seen years of stronger growth and years of weaker growth in the past. This mostly can be explained by factors such as new product introductions, e.g. Watch or iPad, and by the strength of the respective current iPhone models, which see varying demand depending on the year. Other factors, such as economic growth or trade issues, play a role as well.\nData by YCharts\nOverall, revenues have grown by 154% over the last decade, but as we see in the above chart, revenue growth has been relatively uneven. During the early 2010s, Apple generated massive growth on the back of the iPhones \"road to victory\", whereas revenue growth declined to a much slower pace in the following years. There were even some years during which revenues declined on a year-over-year basis, such as 2016. The average annual revenue growth pace was 10% over the last decade, but when we factor in that this was lifted up by the very strong growth in 2011 and 2012, it may not be too reasonable to assume that Apple will grow by 10% a year in the future, too. Investors should also consider that maintaining a high growth rate becomes ever more difficult the larger a company gets. This does, however, not mean that Apple's revenue growth will slow down to zero.\nOn the back of price increases for its products and the potential for market share gains in high-growth countries such as China, where more and more people will be able to buy Apple's higher-priced products, it seems reasonable to assume that Apple will generate at least some growth from its core businesses. Add in growth in the services segment - people use their phones more and more, which should lead to higher app spending - and consider the potential for new product launches (although I assume none will be as massive as the iPhone), and Apple should be able to grow its business at a solid pace. I personally assume that a 5%-7% revenue growth rate could be a realistic estimate for the coming years, although some readers will of course have different opinions.\nApple's shareholder returns\nApple has lowered its share count massively in the past, as shown above, and it is, I believe, reasonable to assume that the same will happen going forward. Over the last decade, Apple bought back 36% of its shares. If the same were to happen over the next decade, each remaining share's portion of the company's value would rise by 56%, or 4.6% annualized. Due to the fact that Apple's current valuation is significantly higher than its historic valuation, buybacks could be less impactful in the future, though. Apple has, for example, only reduced its share count by 2.6% over the last year.\nThis is why I believe that the share count will not decline by another 36% over the coming decade. When we adjust that downward to 25%, this would result in a ~3% annual tailwind for Apple's growth when we look at per-share metrics, which are the deciding factor for Apple's share price growth. Combined with my 5%-7% business growth estimate, I thus assume that Apple will grow by 8%-10% on a per-share basis in the long term.\nApple's future valuation\nAAPL has been valued in a very wide range in the past, seeing its shares trade for very low multiples at some points, whereas investors were willing to pay significantly more at other times:\nData by YCharts\nShares could, five years ago, be bought for a very low 10x net earnings, which naturally was a great time to enter or expand positions. In late 2020, however, shares were trading for as much as 40x the company's net earnings, which seems like a quite high valuation. Right now, AAPL trades at 28x trailing earnings, and at around 24x forward profits. In the above chart, we also see the median earnings multiples over the last 3, 5, 7, and 10 years. It is pretty clear that Apple's valuation has expanded over the years, which is why the median values are higher for the shorter \"lookback\" periods. I do not believe that AAPL will trade at the 15.5x net earnings that it has traded at, on average, over the last decade, as this seems like a rather low valuation for a quality company like Apple with a strong brand, massive scale, great margins, and a fortress balance sheet. On the other hand, I also don't believe that Apple will trade at a 24-28x earnings multiple forever - for a company that generates solid but unspectacular business growth in the mid-single-digits, that seems quite expensive. This is especially true when we consider that interest rates will likely be higher a decade from now, which should pressure valuations for all equities, all else equal. I thus believe that a valuation of around 20x net earnings could be a reasonable estimate for 2031, which would be more or less in line with the 3-year median earnings multiple.\nIs AAPL A Buy Or Sell Now\nStarting our calculation with an EPS estimate of $5.15 for 2021 and assuming that this will grow by 7%-10% a year through 2031, we reach an EPS range of $10.10 to $13.40. Putting a 20x earnings multiple on that leads to a target price of around $200-$270/share. At the midpoint of around $235, shares would thus see gains of around 90% from the current level, or around 6.5% annualized. That surely is not a bad return, and when we add in the dividend, we would get to an annualized return of roughly 7%. This is, on the other hand, also not an outrageously great return, I believe.\nAAPL has, I believe, significant upside potential over the next decade, but that should not be a large surprise - many companies will see significant growth over a time span this long. I personally am not too excited about a 7% expected long-term return. When we consider that shares do have considerable downside risk in the next 1-3 years if Apple's valuation declines, e.g. due to rising interest rates, it may be a better choice to stay on the sidelines for now. Long-term investors will likely not do badly when they buy shares at current levels, but they will likely also not do great. For now, I'd rate Apple a hold, and a potential buy if its valuation comes closer to the longer-term average. Those that are more optimistic about new product launches may disagree and favor buying here, but it could turn out that waiting for a better opportunity is the best choice here.\nSumming it up, I'd say shares do have significant upside potential over the next decade, but the upside potential is not large enough to make me buy shares at current, elevated, valuations.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3930,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150149054,"gmtCreate":1624890796078,"gmtModify":1633947401345,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150149054","repostId":"1103992527","repostType":4,"isVote":1,"tweetType":1,"viewCount":1645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":111764866,"gmtCreate":1622700937655,"gmtModify":1634098990248,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Incredible","listText":"Incredible","text":"Incredible","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/111764866","repostId":"1115876867","repostType":4,"isVote":1,"tweetType":1,"viewCount":1373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":312291758,"gmtCreate":1612148494574,"gmtModify":1703757954531,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/312291758","repostId":"2107292126","repostType":4,"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667803686145","idStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188169824,"gmtCreate":1623424494068,"gmtModify":1634033330380,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Agree!","listText":"Agree!","text":"Agree!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/188169824","repostId":"1146386859","repostType":4,"isVote":1,"tweetType":1,"viewCount":1837,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":382016755,"gmtCreate":1613301350077,"gmtModify":1634553975668,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Great to know","listText":"Great to know","text":"Great to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382016755","repostId":"2110026963","repostType":4,"isVote":1,"tweetType":1,"viewCount":2935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":315852877,"gmtCreate":1612234608899,"gmtModify":1703759111812,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315852877","repostId":"1155510692","repostType":4,"isVote":1,"tweetType":1,"viewCount":487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160075690,"gmtCreate":1623767905210,"gmtModify":1634028595287,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good to know","listText":"Good to know","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160075690","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=zh_CN&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-15 17:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160072591,"gmtCreate":1623767892913,"gmtModify":1634028595988,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good to know","listText":"Good to know","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160072591","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=zh_CN&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up<blockquote>Novavax与辉瑞与Moderna：COVID-19疫苗如何叠加</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-06-15 17:52</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p><p><blockquote>“迟到总比不到好”<b>诺瓦瓦克斯公司。</b>NVAX，这家生物制药公司终于抽出时间宣布了NVX-CoV2371（其针对新型冠状病毒病的候选疫苗）3期研究美国和墨西哥部分的中期结果。</blockquote></p><p> Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p><p><blockquote>以下是Novavax候选疫苗和领跑者的比较视角，即<b>辉瑞公司。</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>莫德纳公司。</b>MRNA，两者都有授权疫苗上市。</blockquote></p><p> <b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p><p><blockquote><b>疫苗类型：</b>Novavax的NVX-CoV2371是一种基于重组纳米颗粒蛋白的COVID-19疫苗，与该公司专有的Matrix-M佐剂包装在一起。</blockquote></p><p> The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p><p><blockquote>辉瑞-BioNTech和Moderna的产品是mRNA疫苗，或通过使用一种称为mRNA的遗传密码来发挥作用的现代疫苗，这种遗传密码指示我们的免疫细胞制造刺突蛋白，刺突蛋白存在于导致新冠肺炎的病毒表面。</blockquote></p><p> This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p><p><blockquote>这种刺突蛋白虽然无害，但能够触发我们的免疫系统产生抗体，防止未来的感染。</blockquote></p><p> Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p><p><blockquote>Novavax的疫苗是一种蛋白质佐剂，含有冠状病毒本身的刺突蛋白，但配方为纳米颗粒，不会导致疾病。然后，注射的疫苗刺激免疫系统产生抗体和T细胞免疫反应。</blockquote></p><p> <b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p><p><blockquote><b>疫苗剂量：</b>这三家公司的疫苗都需要接种两剂。辉瑞的每剂由30 mcg和Moderna的100 mcg组成，而Novavax的每剂疫苗由5 mcg NVX-CoV2371和50 mcg Matrix-M1佐剂组成，它们是共同配制的。</blockquote></p><p> The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p><p><blockquote>辉瑞和Novavax的两种剂量（初免剂量和加强剂量）之间的间隔为21天，Moderna为28天。</blockquote></p><p> <b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p><p><blockquote><b>目标人群：</b>辉瑞-BioNTech最初的后期试验在16岁及以上的参与者中评估了疫苗。该试验招募了43,448名参与者。</blockquote></p><p> Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p><p><blockquote>Moderna的3期COVE研究招募了30,000名18岁及以上的参与者。</blockquote></p><p> Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p><p><blockquote>此后，这两家公司获得了各自疫苗用于青少年的授权。</blockquote></p><p> Bothcompanieshave also initiated studies in the pediatric population.</p><p><blockquote>两家公司还启动了针对儿科人群的研究。</blockquote></p><p> Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p><p><blockquote>Novavax的研究在美国和墨西哥的119个地点招募了29,960名18岁及以上的参与者。PREVENT-19的安慰剂对照部分继续在12岁至18岁以下的青少年中进行，最近完成了2,248名参与者的招募。</blockquote></p><p> <b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p><p><blockquote><b>疫苗物流：</b>辉瑞公司最近获得了FDA的授权，可以将未稀释、解冻的疫苗瓶在2°C至8°C的冰箱中储存长达一个月。</blockquote></p><p> Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p><p><blockquote>以前，解冻、未稀释的疫苗瓶可以在冰箱中储存长达五天。Moderna的疫苗在首次使用前可以在2至8°C的冰箱中储存长达30天。</blockquote></p><p> NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p><p><blockquote>NVX-CoV2373在2°-8°C下储存稳定，允许使用现有的疫苗供应链渠道进行分销。它被包装在10剂小瓶中的即用型液体制剂中。</blockquote></p><p> <b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p><p><blockquote><b>疫苗效力：</b>辉瑞-BioNTech去年12月发布的3期试验中期数据显示，该疫苗耐受性良好，在第二剂疫苗接种后7天或更长时间内，在预防新冠肺炎方面表现出95%的疗效。第二次给药后长达六个月发布的更新顶线结果证实疗效为91.3%。</blockquote></p><p> The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p><p><blockquote>该疫苗被发现对美国疾病控制和预防中心定义的严重疾病100%有效，对FDA定义的严重新冠肺炎95.3%有效。在实验室研究中，它也被证明对英国菌株有效。</blockquote></p><p> Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p><p><blockquote>Moderna的疫苗对新冠肺炎的有效性为94.1%。该公司于5月宣布了其2期研究的初步数据，显示向先前接种疫苗的个体给予50微克剂量的mRNA-1273或mRNA-1273.351作为加强剂，增加了针对新型冠状病毒病毒和两种令人担忧的变异体的中和抗体滴度反应，B.1.351，首次在南非发现，P.1，首次在巴西发现。</blockquote></p><p> Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p><p><blockquote>Novavax的研究疫苗对中度和重度疾病表现出100%的保护作用，不涉及令人担忧的变异体或感兴趣的变异体。</blockquote></p><p> Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p><p><blockquote>针对关注变异体和感兴趣变异体，疗效为93.2%，在高危人群（定义为65岁以上或65岁以下，患有某些合并症或经常暴露于新冠肺炎的情况）中，疗效为91%。</blockquote></p><p> Overall efficacy was 90.4%, meeting the primary endpoint.</p><p><blockquote>总疗效为90.4%，达到主要终点。</blockquote></p><p></p><p> <b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p><p><blockquote><b>坎托·菲茨杰拉德谈Novavax的疫苗：</b>Cantor Fitzgerald分析师Charles Duncan在周一早间报告中表示，NVX-2373的一个与众不同之处在于，它对VoC/VoI表现出93.2%的疫苗效力，这证明了对多种新型冠状病毒毒株的保护作用。</blockquote></p><p> \"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p><p><blockquote>该分析师表示：“总体而言，这些结果增强了我们对新型冠状病毒候选疫苗‘2373具有差异化临床和物流特征的信念。”</blockquote></p><p> Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p><p><blockquote>他说，在两项3期临床试验中显示出对新毒株的功效，而不是从培养皿中进行的中和抗体测定中推断出潜在功效，这将NVX-CoV2373与其他获得紧急使用授权的疫苗区分开来。</blockquote></p><p> This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p><p><blockquote>Cantor表示，这一概况降低了'2373新型冠状病毒预防性候选疫苗的监管/商业风险，并且随着2020年3月报告的NanoFlu 3期积极数据，应该会提高Novavax平台的整体形象。</blockquote></p><p> <b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p><p><blockquote><b>疫苗安全性数据：</b>辉瑞-BioNTech的疫苗显示出良好的耐受性和安全性，BNT 162 b 2最常见的不良事件是注射部位的短暂、轻度至中度疼痛、疲劳和头痛，这些通常在两天内消退。</blockquote></p><p> For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p><p><blockquote>对于Moderna，最常见的不良反应包括注射部位疼痛、疲劳、肌痛、关节痛、头痛和注射部位红斑/发红。第二次给药后，mRNA-1273组中引起的不良反应的频率和严重程度增加。</blockquote></p><p> Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p><p><blockquote>Novavax试验的初步安全性数据显示，该疫苗总体耐受性良好。严重和严重不良事件的数量较少，并且在疫苗组和安慰剂组之间平衡。</blockquote></p><p> In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p><p><blockquote>在第1剂和第2剂后7天评估反应原性时，注射部位疼痛和压痛（通常严重程度为轻度至中度）是最常见的局部症状，持续时间少于3天。疲劳、头痛和肌肉疼痛是最常见的全身症状，持续时间不到两天。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185776661,"gmtCreate":1623676310853,"gmtModify":1634030252598,"author":{"id":"3550499772816891","authorId":"3550499772816891","name":"Jpeh","avatar":"https://static.tigerbbs.com/4f74e86286be4e7bdaac05ba96b3a697","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550499772816891","idStr":"3550499772816891"},"themes":[],"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/185776661","repostId":"1182855398","repostType":4,"repost":{"id":"1182855398","kind":"news","pubTimestamp":1623663435,"share":"https://www.laohu8.com/m/news/1182855398?lang=zh_CN&edition=full","pubTime":"2021-06-14 17:37","market":"us","language":"en","title":"Chip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182855398","media":"benzinga","summary":"The ongoing global semiconductor shortage is boosting business opportunities for semiconductor indus","content":"<p><div> The ongoing global semiconductor shortage is boosting business opportunities for semiconductor industry intermediaries, or authorized distributors, as they are able to source parts faster, according ...</p><p><blockquote><div>持续的全球半导体短缺正在增加半导体行业中介或授权分销商的商机，因为他们能够更快地采购零件...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChip Shortage Bringing Record Business For Supply-Chain Intermediaries Avnet, Arrow Electronics: WSJ<blockquote>芯片短缺为供应链中介安富利、艾睿电子带来创纪录的业务量：华尔街日报</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">benzinga</strong><span class=\"h-time small\">2021-06-14 17:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The ongoing global semiconductor shortage is boosting business opportunities for semiconductor industry intermediaries, or authorized distributors, as they are able to source parts faster, according ...</p><p><blockquote><div>持续的全球半导体短缺正在增加半导体行业中介或授权分销商的商机，因为他们能够更快地采购零件...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect\">benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AVGO":"博通","ARW":"艾睿","INTC":"英特尔","AVT":"安富利电子"},"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/21/06/21544070/chip-shortage-bringing-record-business-for-supply-chain-intermediaries-avnet-arrow-elect","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182855398","content_text":"The ongoing global semiconductor shortage is boosting business opportunities for semiconductor industry intermediaries, or authorized distributors, as they are able to source parts faster, according to the WSJreport.\nWhat Happened:Services of electronic component distributors such as Avnet Inc(NASDAQ:AVT) andArrow Electronics Inc(NYSE:ARW) are increasingly sought after from bigger companies such as Intel Corp(NASDAQ:INTC), Samsung Electronics and others, who generally rely on direct purchases and are able to secure supplies on their own, WSJ reported Sunday.\nAs per Peggy Carrieres, Avnet’s vice president for global sales, large buyers are treading on uncharted territory as they engage directly with distributors to hedge against supply chain disruptions or keep tabs on a host of different materials.\nAvnet is an authorized distributor for Intel andBroadcom Inc(NASDAQ:AVGO).\nAs a result, distributors are able to charge more than the usual 10% commission. In addition, higher prices and shipping volumes amid the pandemic have boosted bottom lines for distributors despite an ongoing shortage.\nArrow Electronics, one of the industry’s biggest distributors, saw its operating income from the global components business rise more than 70% in the first three months of the year. Avnet sales rose 14% from a year earlier to $4.9 billion for the quarter ended March 31.\nWhy It Matters:The global chip shortage has forced automakers across the world to halt production lines and the shortage is now impacting consumer electronics as well, includingApple Inc(NASDAQ:AAPL).\nSemiconductor prices have shot up amid the crisis and brokers are quoting five times higher prices than before the pandemic for auto chips, as per WSJ; in some extreme cases, it's reportedly 20 times more.\nPrice Action:Shares of Avnet, which have risen 25% so far this year, closed 1% higher at $43.9 on Friday. Arrow Electronics shares, which have risen 24% year-to-date, closed 0.25% lower at $120.9 on Friday.","news_type":1,"symbols_score_info":{"ARW":0.9,"INTC":0.9,"AVT":0.9,"AVGO":0.9}},"isVote":1,"tweetType":1,"viewCount":2456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}